@NP	Chronic Spinal Injury	1
@NP	Repair by Olfactory Bulb	23
@NP	Repair	23
@NP	Olfactory Bulb	33
@NP	Ensheathing	48
@NP	Glia and Feasibility for Autologous Therapy Cintia Mun˜oz	60
@NP	Glia and Feasibility	60
@NP	Autologous Therapy Cintia Mun˜oz	85
@NP	Quiles , PhD , Fernando F.	119
@NP	Quiles , PhD	119
@NP	Fernando F.	132
@NP	Santos-Benito , PhD , M.	144
@NP	Santos-Benito	144
@NP	PhD , M.	159
@NP	Beatriz Llamusı '	167
@NP	Llamusı '	175
@NP	PhD	185
@NP	Almudena Ramo ' n-Cueto , MD	194
@NP	Almudena Ramo '	194
@NP	PhD Abstract Olfactory bulb ensheathing glia -LRB- OB-OEG -RRB-	221
@NP	PhD Abstract Olfactory bulb ensheathing glia	221
@NP	OB-OEG	268
@NP	repair of spinal cord injury -LRB- SCI -RRB- in rats	284
@NP	repair	284
@NP	spinal cord injury -LRB- SCI -RRB- in rats	294
@NP	spinal cord injury -LRB- SCI -RRB-	294
@NP	spinal cord injury	294
@NP	SCI	314
@NP	rats	322
@NP	transplantation at acute or subacute -LRB- up to 45 days -RRB- stages	333
@NP	transplantation	333
@NP	acute or subacute -LRB- up to 45 days -RRB- stages	352
@NP	45 days	377
@NP	The most relevant clinical scenario in humans	394
@NP	The most relevant clinical scenario	394
@NP	humans	433
@NP	chronic SCI	453
@NP	no more major cellular or molecular changes	475
@NP	the injury site	528
@NP	this	545
@NP	the third month in rodents	563
@NP	the third month	563
@NP	rodents	582
@NP	adult OB-OEG grafts	599
@NP	repair of severe chronic SCI	627
@NP	repair	627
@NP	severe chronic SCI	637
@NP	Rats with complete SCI that were transplanted with OB-OEG 4 months after injury	691
@NP	Rats	691
@NP	complete SCI	701
@NP	OB-OEG	742
@NP	4 months	749
@NP	injury	764
@NP	progressive improvement	781
@NP	motor function and axonal regeneration	808
@NP	motor function	808
@NP	axonal regeneration	827
@NP	different brainstem nuclei	852
@NP	the SCI site	897
@NP	A positive correlation between motor outcome and axonal regeneration	911
@NP	A positive correlation	911
@NP	motor outcome and axonal regeneration	942
@NP	motor outcome	942
@NP	axonal regeneration	960
@NP	a role	990
@NP	brainstem neurons	1001
@NP	the recovery	1022
@NP	Functional and histological outcomes	1036
@NP	transplantation	1094
@NP	subacute or chronic stages	1113
@NP	autologous transplantation	1147
@NP	a feasible approach	1177
@NP	there	1200
@NP	a time frame for patient stabilization and OEG preparation	1209
@NP	a time frame	1209
@NP	patient stabilization and OEG preparation	1226
@NP	patient stabilization	1226
@NP	OEG preparation	1252
@NP	the healing effects of OB-OEG on established injuries	1279
@NP	the healing effects	1279
@NP	OB-OEG on established injuries	1302
@NP	OB-OEG	1302
@NP	established injuries	1312
@NP	new therapeutic opportunities	1343
@NP	chronic SCI patients	1377
@NP	INTRODUCTION Most spinal cord injuries -LRB- SCIs -RRB-	1400
@NP	INTRODUCTION Most spinal cord injuries	1400
@NP	INTRODUCTION	1400
@NP	Most	1413
@NP	spinal cord injuries	1418
@NP	SCIs	1440
@NP	permanent and irreversible functional deficits	1452
@NP	The devastating prognosis for people experiencing severe SCI	1500
@NP	The devastating prognosis	1500
@NP	people experiencing severe SCI	1530
@NP	people	1530
@NP	severe SCI	1550
@NP	an impetus to search for therapies aimed at curing this chronic pathology	1574
@NP	therapies aimed at curing this chronic pathology	1599
@NP	therapies	1599
@NP	this chronic pathology	1625
@NP	the use of olfactory ensheathing glia -LRB- OEG -RRB- transplantation	1649
@NP	the use	1649
@NP	olfactory ensheathing glia -LRB- OEG -RRB- transplantation	1660
@NP	OEG	1688
@NP	a promising repair strategy	1712
@NP	There	1741
@NP	more than 40 articles	1751
@NP	positive effects of OEG	1783
@NP	positive effects	1783
@NP	OEG	1803
@NP	SCI of various types and severities -LRB- 1 -RRB-	1813
@NP	SCI	1813
@NP	various types and severities -LRB- 1 -RRB-	1820
@NP	various types and severities	1820
@NP	1	1850
@NP	most of these	1854
@NP	most	1854
@NP	these	1862
@NP	spinal cord trauma -LRB- 2Y9 -RRB- , including contusion -LRB- 10 -RRB-	1875
@NP	spinal cord trauma -LRB- 2Y9 -RRB-	1875
@NP	spinal cord trauma	1875
@NP	2Y9	1895
@NP	contusion -LRB- 10 -RRB-	1911
@NP	contusion	1911
@NP	10	1922
@NP	there	1931
@NP	13 studies that show no or limited beneficial effects	1941
@NP	13 studies	1941
@NP	no or limited beneficial effects	1962
@NP	no	1962
@NP	limited beneficial effects	1968
@NP	The differences	1996
@NP	the sources of cells	2028
@NP	the sources	2028
@NP	cells	2043
@NP	ages of the animals	2050
@NP	ages	2050
@NP	the animals	2058
@NP	the methods used for culture and transplantation	2075
@NP	the methods	2075
@NP	culture and transplantation	2096
@NP	the third week in vitro , adult rodent olfactory bulb -LRB- OB -RRB-	2131
@NP	the third week in vitro , adult rodent olfactory bulb	2131
@NP	third week	2135
@NP	OB	2185
@NP	OEG become senescent and have an associated change in phenotype -LRB- 11 -RRB-	2189
@NP	OEG	2189
@NP	an associated change in phenotype -LRB- 11 -RRB-	2219
@NP	an associated change	2219
@NP	phenotype -LRB- 11 -RRB-	2243
@NP	phenotype	2243
@NP	11	2254
@NP	grafting of older cultures	2265
@NP	grafting	2265
@NP	older cultures	2277
@NP	cell survival and/or migration -LRB- 12Y15 -RRB-	2307
@NP	cell survival and/or migration	2307
@NP	cell survival	2307
@NP	migration	2328
@NP	12Y15	2339
@NP	OEG	2362
@NP	the olfactory bulb -LRB- central -RRB-	2371
@NP	the olfactory bulb	2371
@NP	central	2391
@NP	the epithelium -LRB- peripheral -RRB-	2408
@NP	the epithelium	2408
@NP	peripheral	2425
@NP	a debated issue	2445
@NP	OEG	2480
@NP	they	2509
@NP	inferior migratory and growth-promoting properties	2527
@NP	16Y18	2579
@NP	bulbar OEG -LRB- 2Y9 -RRB-	2600
@NP	bulbar OEG	2600
@NP	2Y9	2612
@NP	these studies and the prospect for autologous therapy	2627
@NP	these studies	2627
@NP	the prospect for autologous therapy	2645
@NP	the prospect	2645
@NP	autologous therapy	2662
@NP	we	2682
@NP	adult nonsenescent OEG of bulbar origin	2690
@NP	adult nonsenescent OEG	2690
@NP	bulbar origin	2716
@NP	this study	2733
@NP	most of the previous studies	2748
@NP	most	2748
@NP	the previous studies	2756
@NP	OEG	2778
@NP	SCI -LRB- the acute stage -RRB-	2823
@NP	SCI	2823
@NP	the acute stage	2828
@NP	many patients	2854
@NP	several weeks or even months for clinical stabilization	2873
@NP	several weeks	2873
@NP	months for clinical stabilization	2895
@NP	months	2895
@NP	clinical stabilization	2906
@NP	a delayed transplant paradigm	2939
@NP	autologous transplantation	3017
@NP	cell preparation	3059
@NP	time	3085
@NP	an intervention several months after SCI	3098
@NP	an intervention several months	3098
@NP	SCI	3135
@NP	a more realistic paradigm	3142
@NP	Experimental OB-OEG grafting	3169
@NP	7 and 30 days -LRB- 10 , 19 -RRB-	3219
@NP	7 and 30 days	3219
@NP	10	3234
@NP	19	3238
@NP	45 days -LRB- 20 -RRB-	3259
@NP	20	3268
@NP	the subacute stage -LRB- 21 , 22 -RRB-	3305
@NP	the subacute stage	3305
@NP	21	3325
@NP	22	3329
@NP	the absence of further manipulation	3337
@NP	the absence	3337
@NP	further manipulation	3352
@NP	no more cellular and molecular changes	3382
@NP	more cellular	3385
@NP	molecular changes	3403
@NP	SCIs	3428
@NP	the chronic stage	3457
@NP	the third month in rodents -LRB- 21 , 22 -RRB-	3491
@NP	the third month	3491
@NP	rodents -LRB- 21 , 22 -RRB-	3510
@NP	rodents	3510
@NP	21	3519
@NP	22	3523
@NP	we	3534
@NP	the repair efficacy	3548
@NP	OB-OEG	3571
@NP	the chronic stage into the injury site , and after complete SCI	3589
@NP	the chronic stage	3589
@NP	the injury site	3612
@NP	complete SCI	3639
@NP	axonal regeneration	3664
@NP	plasticity of spared fibers	3696
@NP	plasticity	3696
@NP	spared fibers	3710
@NP	We	3725
@NP	functional and histological outcomes	3742
@NP	the subacute stage	3796
@NP	the regeneration	3830
@NP	relevant descending motor tracts at both subacute and chronic stages	3850
@NP	relevant descending motor tracts	3850
@NP	both subacute and chronic stages	3886
@NP	both subacute	3886
@NP	chronic stages	3904
@NP	MATERIALS AND METHODS	3921
@NP	The experimental procedures	3943
@NP	the recommendations of the European Union	3982
@NP	the recommendations	3982
@NP	the European Union	4005
@NP	the United States Department of Health	4028
@NP	the United States Department	4028
@NP	Health	4060
@NP	the care and use of laboratory animals	4071
@NP	the care and use	4071
@NP	laboratory animals	4091
@NP	the Ethics Committee of our institution	4131
@NP	the Ethics Committee	4131
@NP	our institution	4155
@NP	OEG Cultures	4172
@NP	Adult OBs	4190
@NP	Primary cultures of OB-OEG	4200
@NP	Primary cultures	4200
@NP	OB-OEG	4220
@NP	the first 2 olfactory bulb layers of 2	4246
@NP	the first 2 olfactory bulb layers	4246
@NP	2	4283
@NP	2.5-month-old Wistar Hannover rats	4289
@NP	Harlan Laboratories	4325
@NP	Barcelona	4346
@NP	Spain	4357
@NP	p75 receptorYexpressing OB-OEG	4365
@NP	7 days	4410
@NP	2 , 11	4456
@NP	2	4456
@NP	11	4459
@NP	They	4464
@NP	D/F -10 S	4486
@NP	1:1 DMEM	4495
@NP	Ham F-12 ; Gibco-Invitrogen , Madrid , Spain ; 10 % fetal bovine serum	4504
@NP	Ham F-12	4504
@NP	Gibco-Invitrogen , Madrid , Spain ; 10 % fetal bovine serum	4514
@NP	Gibco-Invitrogen , Madrid , Spain	4514
@NP	10 % fetal bovine serum	4547
@NP	37-C , 5 % carbon dioxide	4574
@NP	37-C	4574
@NP	5 % carbon dioxide	4580
@NP	2 days after purification	4602
@NP	2 days	4602
@NP	purification	4615
@NP	2 µmol/L forskolin -LRB- Sigma - Aldrich Quı ' mica , Madrid , Spain -RRB-	4629
@NP	2 µmol/L forskolin	4629
@NP	Sigma	4649
@NP	Aldrich Quı ' mica , Madrid , Spain	4656
@NP	Aldrich Quı ' mica	4656
@NP	Aldrich Quı '	4656
@NP	Madrid , Spain	4674
@NP	20 µg/mL bovine pituitary extract	4693
@NP	20 µg/mL	4693
@NP	Biomedical Technologies	4728
@NP	Inc	4753
@NP	Stoughton , MA	4758
@NP	Pure p75-OEG	4785
@NP	less than 2 weeks	4816
@NP	senescence -LRB- 11 -RRB-	4843
@NP	senescence	4843
@NP	11	4855
@NP	Cells	4860
@NP	the flasks	4885
@NP	bisbenzimide -LRB- Hoechst 33342 ; Sigma-Aldrich Quı ' mica -RRB-	4910
@NP	bisbenzimide	4910
@NP	Hoechst 33342 ; Sigma-Aldrich Quı ' mica	4924
@NP	Hoechst 33342	4924
@NP	Sigma-Aldrich Quı ' mica	4939
@NP	Sigma-Aldrich	4939
@NP	Quı ' mica	4953
@NP	Quı '	4953
@NP	a density of 100,000 cells/µL	4984
@NP	a density	4984
@NP	100,000 cells/µL	4997
@NP	Dulbecco	5017
@NP	Eagle medium -LRB- DMEM -RRB- , as previously described	5035
@NP	Eagle medium	5035
@NP	DMEM	5049
@NP	2 , 4 , 23 , 24	5081
@NP	2	5081
@NP	4	5084
@NP	23	5087
@NP	24	5091
@NP	Surgery and OB-OEG Transplantation Adult	5096
@NP	female Wistar Hannover rats -LRB- aged 2.5 Y3 months ,	5137
@NP	female Wistar Hannover rats	5137
@NP	aged 2.5 Y3 months	5166
@NP	aged 2.5	5166
@NP	Y3 months	5174
@NP	200-230 g , n = 28 -RRB-	5194
@NP	200-230 g	5194
@NP	n = 28	5205
@NP	n	5205
@NP	28	5209
@NP	anesthetized with isoflurane and N2	5218
@NP	anesthetized	5218
@NP	isoflurane and N2	5236
@NP	O2 -LRB- 40:60 -RRB- , and a laminectomy to expose the T8 to T9 segments	5254
@NP	O2	5254
@NP	40:60	5258
@NP	a laminectomy to expose the T8 to T9 segments	5270
@NP	the T8	5294
@NP	T9 segments	5304
@NP	22 of the animals	5334
@NP	22	5334
@NP	the animals	5340
@NP	the dura	5353
@NP	the spinal cords	5377
@NP	microscissors	5426
@NP	The stumps	5441
@NP	completeness of the lesion -LRB- Fig. 1A -RRB- -LRB- 4 -RRB-	5474
@NP	completeness	5474
@NP	the lesion -LRB- Fig. 1A -RRB- -LRB- 4 -RRB-	5490
@NP	the lesion -LRB- Fig. 1A -RRB-	5490
@NP	the lesion	5490
@NP	Fig. 1A	5502
@NP	4	5512
@NP	The paraplegic animals	5516
@NP	3 groups	5562
@NP	subacute	5575
@NP	-LRB- SA -RRB- ,	5584
@NP	-LRB- SA -RRB-	5584
@NP	chronic	5593
@NP	-LRB- Chr -RRB- , and	5601
@NP	-LRB- Chr -RRB-	5601
@NP	3 -RRB- nontransplanted -LRB- Non-T -RRB- in a second	5612
@NP	3 -RRB- nontransplanted -LRB- Non-T -RRB- in	5612
@NP	Non-T	5632
@NP	a second	5642
@NP	surgery	5651
@NP	The SA rats -LRB- n = 5 -RRB-	5660
@NP	The SA rats	5660
@NP	n	5673
@NP	5	5677
@NP	p75 OB-OEG at 1 month , and Chr rats -LRB- n = 5 -RRB-	5703
@NP	p75 OB-OEG	5703
@NP	1 month , and Chr rats -LRB- n = 5 -RRB-	5717
@NP	1 month	5717
@NP	Chr rats	5730
@NP	n	5740
@NP	5	5744
@NP	4 months	5750
@NP	SCI	5765
@NP	Non-T animals -LRB- n = 12 -RRB-	5770
@NP	Non-T animals	5770
@NP	n	5785
@NP	12	5789
@NP	DMEM	5838
@NP	1 -LRB- n = 6 -RRB- or 4 -LRB- n = 6 -RRB-	5849
@NP	1	5849
@NP	n	5852
@NP	6	5856
@NP	4	5862
@NP	n	5865
@NP	6	5869
@NP	months	5872
@NP	the sham-operated group	5883
@NP	6 more animals	5908
@NP	a second surgery	5956
@NP	1 -LRB- n = 3 -RRB- and 4 -LRB- n = 3 -RRB- months	5979
@NP	1 -LRB- n = 3 -RRB-	5979
@NP	1	5979
@NP	n	5982
@NP	3	5986
@NP	4 -LRB- n = 3 -RRB- months	5993
@NP	4	5993
@NP	n	5996
@NP	3	6000
@NP	months	6003
@NP	the second surgery	6014
@NP	the connective tissue	6034
@NP	the resin bridge	6079
@NP	the spinal cord -LRB- Fig. 1D -RRB-	6106
@NP	the spinal cord	6106
@NP	Fig. 1D	6123
@NP	the injury region	6154
@NP	Glial and fibrous scars , created between the spinal cord stumps ,	6173
@NP	Glial and fibrous scars	6173
@NP	the spinal cord stumps	6214
@NP	Fig. 1E	6256
@NP	The OB-OEG	6266
@NP	both caudal and rostral intact spinal cord stumps	6311
@NP	1 mm	6365
@NP	the stump border -LRB- Fig. 1F -RRB- , as previously described	6375
@NP	the stump border -LRB- Fig. 1F -RRB-	6375
@NP	the stump border	6375
@NP	Fig. 1F	6393
@NP	4	6428
@NP	23	6431
@NP	Cells	6436
@NP	the midline of each stump	6459
@NP	the midline	6459
@NP	each stump	6474
@NP	ventral to dorsal , into 4 sites at 1.3 , 1.0 , 0.8 , and 0.5 mm	6491
@NP	dorsal	6502
@NP	4 sites at 1.3 , 1.0 , 0.8 , and 0.5	6515
@NP	4 sites	6515
@NP	1.3 , 1.0 , 0.8 , and 0.5	6526
@NP	1.3	6526
@NP	1.0 , 0.8 , and 0.5	6531
@NP	Each site	6567
@NP	0.5 µL of 50,000 OEG -LRB- 200,000 per stump -RRB-	6586
@NP	0.5 µL	6586
@NP	50,000 OEG -LRB- 200,000 per stump -RRB-	6596
@NP	50,000 OEG	6596
@NP	200,000 per stump	6608
@NP	200,000	6608
@NP	stump	6620
@NP	Nontransplanted animals	6628
@NP	0.5 µL of DMEM	6671
@NP	0.5 µL	6671
@NP	DMEM	6681
@NP	sham controls	6699
@NP	both surgeries	6735
@NP	spinal cords	6751
@NP	durafilm -LRB- Ferrosan , London , UK -RRB-	6782
@NP	durafilm	6782
@NP	Ferrosan	6792
@NP	London	6802
@NP	UK	6810
@NP	Vertebral columns	6815
@NP	a resin bridge	6857
@NP	adjacent vertebrae	6880
@NP	Fig. 1C	6900
@NP	an autopolymerizing acrylic resin	6917
@NP	Duralay ; Reliance Dental Manufacturing Co	6952
@NP	Duralay	6952
@NP	Reliance Dental Manufacturing Co	6961
@NP	Worth , IL	6995
@NP	Worth	6995
@NP	IL	7002
@NP	25	7007
@NP	26	7011
@NP	Animal Care , Physiotherapy , and Rehabilitation	7016
@NP	Animal Care	7016
@NP	Physiotherapy	7029
@NP	Rehabilitation	7048
@NP	surgery	7081
@NP	1 mL	7090
@NP	Ringer 's lactate solution and analgesic magnesium metamizol	7098
@NP	Ringer 's	7098
@NP	Nolotil	7159
@NP	Boehringer Ingelheim	7168
@NP	Barcelona , Spain	7190
@NP	An antibiotic	7242
@NP	Augmentin	7257
@NP	amoxicillin/clavulanic acid , 1 g/200 mg ; GlaxoSmithKline , Madrid , Spain	7268
@NP	amoxicillin/clavulanic acid	7268
@NP	1 g/200 mg ; GlaxoSmithKline	7297
@NP	1 g/200 mg	7297
@NP	GlaxoSmithKline	7309
@NP	Madrid , Spain	7326
@NP	every 8 hours	7378
@NP	Urinary bladder	7393
@NP	4 times a day	7432
@NP	4 times	7432
@NP	a day	7440
@NP	autonomous voidance and then once daily	7452
@NP	autonomous voidance	7452
@NP	then once daily	7476
@NP	Detailed postoperative care	7493
@NP	27	7541
@NP	paraplegic rats	7554
@NP	good condition	7573
@NP	they	7589
@NP	active and passive range of motion	7603
@NP	active and passive range	7603
@NP	motion	7631
@NP	Active range of motion	7639
@NP	Active range	7639
@NP	motion	7655
@NP	the	7682
@NP	test -LRB- Appendix 1 -RRB-	7695
@NP	test	7695
@NP	Appendix 1	7701
@NP	once a week	7713
@NP	Daily passive range of motion	7726
@NP	Daily passive range	7726
@NP	motion	7749
@NP	movement of joints	7765
@NP	movement	7765
@NP	joints	7777
@NP	the level of injury -LRB- 25 times each joint -RRB-	7790
@NP	the level	7790
@NP	injury -LRB- 25 times each joint -RRB-	7803
@NP	injury	7803
@NP	25 times each joint	7811
@NP	25 times	7811
@NP	each joint	7820
@NP	massages of muscles and skin	7836
@NP	massages	7836
@NP	muscles and skin	7848
@NP	bone prominences	7870
@NP	All animals	7888
@NP	12 months	7928
@NP	the first surgery -LRB- lesion surgery -RRB-	7944
@NP	the first surgery	7944
@NP	lesion surgery	7963
@NP	a third surgery for tracer injection -LRB- see below -RRB-	7996
@NP	a third surgery	7996
@NP	tracer injection	8016
@NP	All paraplegic animals with a complete lesion	8046
@NP	All paraplegic animals	8046
@NP	a complete lesion	8074
@NP	good and stable clinical condition for 1 year	8116
@NP	good and stable clinical condition	8116
@NP	1 year	8155
@NP	paraplegia	8169
@NP	animals	8181
@NP	2 additional surgeries	8193
@NP	one for OB-OEG transplantation	8217
@NP	one	8217
@NP	OB-OEG transplantation	8225
@NP	another for tracer injection	8252
@NP	another	8252
@NP	tracer injection	8264
@NP	the time of the last surgery	8285
@NP	the time	8285
@NP	the last surgery	8297
@NP	the animals	8315
@NP	15 months	8367
@NP	Animal care	8383
@NP	those used for humans -LRB- 27 -RRB-	8412
@NP	those	8412
@NP	humans -LRB- 27 -RRB-	8427
@NP	humans	8427
@NP	27	8435
@NP	Functional Analysis	8440
@NP	A detailed description of the climbing test	8460
@NP	A detailed description	8460
@NP	the climbing test	8486
@NP	this study	8512
@NP	and	8551
@NP	Appendix 1	8571
@NP	supplemental data	8599
@NP	Video	8618
@NP	Supplemental Digital Content 1 , http://links.lww.com/NEN/A62	8625
@NP	Supplemental Digital Content 1	8625
@NP	http://links.lww.com/NEN/A62	8657
@NP	the animals	8710
@NP	1 month	8727
@NP	the first surgery	8759
@NP	Comparison of the performance of transplanted and Non-T rats	8778
@NP	Comparison	8778
@NP	the performance of transplanted and Non-T rats	8792
@NP	the performance	8792
@NP	transplanted and Non-T rats	8811
@NP	transplanted	8811
@NP	Non-T rats	8828
@NP	1	8847
@NP	month	8849
@NP	the first surgery -LRB- lesion -RRB- -LRB- Fig. 2 -RRB-	8861
@NP	the first surgery -LRB- lesion -RRB-	8861
@NP	the first surgery	8861
@NP	lesion	8880
@NP	Fig. 2	8889
@NP	Tracer Injection	8898
@NP	12 months	8918
@NP	lesion	8934
@NP	all animals	8942
@NP	a third surgery	8964
@NP	tracer injection	8984
@NP	A cocktail	9002
@NP	25 % horseradish peroxidase and 5 % wheat germ agglutininYhorseradish peroxidase	9016
@NP	25 % horseradish peroxidase	9016
@NP	5 % wheat germ agglutininYhorseradish peroxidase	9047
@NP	5 % wheat germ	9047
@NP	agglutininYhorseradish peroxidase	9061
@NP	Sigma-Aldrich Quı ' mica	9096
@NP	Sigma-Aldrich Quı '	9096
@NP	0.9 % NaCl	9123
@NP	the caudal stump	9167
@NP	0.5 cm	9188
@NP	its edge as	9200
@NP	peroxidase	9233
@NP	13 sites -LRB- 0.1 µL/site -RRB-	9262
@NP	13 sites	9262
@NP	0.1 µL/site	9272
@NP	the midline -LRB- 5 injections -RRB-	9303
@NP	the midline	9303
@NP	5 injections	9316
@NP	0.8 mm	9337
@NP	the left and right -LRB- 4 injections in each side -RRB-	9347
@NP	the left and right	9347
@NP	4 injections in each side	9367
@NP	4 injections	9367
@NP	each side	9383
@NP	2	9397
@NP	1.6	9400
@NP	1.2	9405
@NP	0.8	9410
@NP	0.4 mm in the midline	9419
@NP	0.4 mm	9419
@NP	the midline	9429
@NP	1.6	9442
@NP	1.2	9447
@NP	0.8	9452
@NP	0.4 mm in left and right sides	9457
@NP	0.4 mm	9457
@NP	left and right sides	9467
@NP	Rats	9489
@NP	48 hours	9518
@NP	perfusion	9534
@NP	This retrograde tracer	9545
@NP	axons either passing through or terminating at the site of injection	9586
@NP	axons	9586
@NP	the site of injection	9633
@NP	the site	9633
@NP	injection	9645
@NP	it	9663
@NP	axons	9677
@NP	at least 0.5 cm	9696
@NP	the lesion	9719
@NP	Histological Processing Animals	9731
@NP	4 % paraformaldehyde	9782
@NP	the spinal cords and brainstems	9803
@NP	the spinal cords	9803
@NP	brainstems	9824
@NP	5 hours	9868
@NP	Coronal sections of the brainstems	9877
@NP	Coronal sections	9877
@NP	the brainstems	9897
@NP	longitudinal sagittal sections of the spinal cords	9916
@NP	longitudinal sagittal sections	9916
@NP	the spinal cords	9950
@NP	a cryostat -LRB- -20 °C , 20-µm sections -RRB-	9979
@NP	a cryostat	9979
@NP	-20 °C , 20-µm sections	9991
@NP	-20 °C	9991
@NP	20-µm sections	9998
@NP	Consecutive sections of the whole structures	10015
@NP	Consecutive sections	10015
@NP	the whole structures	10039
@NP	different slides	10080
@NP	peroxidase detection and immunohistochemistry	10115
@NP	peroxidase detection	10166
@NP	the entire brainstem	10188
@NP	20 µm	10226
@NP	sections	10237
@NP	each region of interest	10284
@NP	each region	10284
@NP	interest	10299
@NP	peroxidase detection	10313
@NP	sections -LRB- 100 µm -RRB-	10350
@NP	sections	10350
@NP	100 µm	10360
@NP	the entire brainstem	10391
@NP	these sections	10416
@NP	the peroxidase-labeled somata	10432
@NP	the chromogen diaminobenzidine -LRB- Vector Laboratories , Burlingame , CA -RRB-	10481
@NP	the chromogen diaminobenzidine	10481
@NP	Vector Laboratories	10513
@NP	Burlingame	10534
@NP	CA	10546
@NP	the signal	10563
@NP	sections	10575
@NP	an antibody	10607
@NP	wheat germ agglutinin	10627
@NP	anti-wheat germ agglutinin , 1:250	10650
@NP	anti-wheat germ agglutinin	10650
@NP	1:250	10678
@NP	4-C	10698
@NP	a biotinylated-conjugated secondary antibody	10707
@NP	1:200 , 45 minutes	10753
@NP	1:200	10753
@NP	45 minutes	10760
@NP	the Vectastain Elite ABC	10792
@NP	standard kit -LRB- antibodies and kit from Vector Laboratories -RRB-	10817
@NP	standard kit	10817
@NP	antibodies and kit from Vector Laboratories	10831
@NP	antibodies and kit	10831
@NP	Vector Laboratories	10855
@NP	Spinal cord sections of 3 animals per group -LRB- n = 9 -RRB-	10877
@NP	Spinal cord sections of 3 animals per group	10877
@NP	Spinal cord sections	10877
@NP	3 animals per group	10901
@NP	3 animals	10901
@NP	group	10915
@NP	n	10922
@NP	9	10926
@NP	peroxidase	10994
@NP	the injury region	11021
@NP	Figure , Supplemental Digital Content 2 , http://links.lww.com/NEN/A63	11040
@NP	Figure	11040
@NP	Supplemental Digital Content 2	11048
@NP	http://links.lww.com/NEN/A63	11080
@NP	Spinal cord sections	11111
@NP	the entire injury region and 2 segments	11143
@NP	the entire injury region	11143
@NP	2 segments	11172
@NP	i.e. from T6 to T10	11200
@NP	i.e.	11200
@NP	T6	11210
@NP	T10	11216
@NP	Appendix 2	11241
@NP	the sections	11262
@NP	we	11304
@NP	the precise location of each section	11322
@NP	the precise location	11322
@NP	each section	11346
@NP	the type of analysis -LRB- see below -RRB-	11373
@NP	the type	11373
@NP	analysis	11385
@NP	these sections	11407
@NP	4 °C with the following primary antibodies	11450
@NP	4 °C	11450
@NP	the following primary antibodies	11459
@NP	polyclonal rabbit	11493
@NP	anti-glial fibrillary acidic protein	11511
@NP	-LSB- GFAP -RSB- Dako	11549
@NP	-LSB- GFAP	11549
@NP	Dako	11556
@NP	Barcelona , Spain ; 1:500	11562
@NP	Barcelona , Spain	11562
@NP	1:500	11580
@NP	reactive astroglia	11596
@NP	the glial scar	11630
@NP	monoclonal mouse anti-neurofilament	11646
@NP	-LSB- NFL -RSB- Hybridoma Bank RT 97 , Iowa City	11683
@NP	-LSB- NFL -RSB- Hybridoma Bank RT 97	11683
@NP	Iowa City	11711
@NP	IA ; 1:1500	11722
@NP	IA	11722
@NP	1:1500	11726
@NP	axons	11743
@NP	polyclonal rabbit antiYRat S100 -LRB- Dako ; 1:100 -RRB- to distinguish OEG	11754
@NP	polyclonal rabbit antiYRat S100	11754
@NP	Dako ; 1:100	11787
@NP	Dako	11787
@NP	1:100	11793
@NP	OEG	11815
@NP	The following day	11820
@NP	sections	11839
@NP	the respective secondary antibodies	11868
@NP	Texas Red	11920
@NP	Jackson ImmunoResearch , West Grove	11931
@NP	Jackson ImmunoResearch	11931
@NP	West Grove	11955
@NP	PA ; 1:500	11967
@NP	PA	11967
@NP	1:500	11971
@NP	Oregon Green	11981
@NP	Molecular ProbesYInvitrogen , Barcelona	11995
@NP	Molecular ProbesYInvitrogen	11995
@NP	Barcelona	12024
@NP	Spain ; 1:500	12035
@NP	Spain	12035
@NP	1:500	12042
@NP	45 minutes at room temperature	12053
@NP	45 minutes	12053
@NP	room temperature	12067
@NP	sections	12093
@NP	Fluoromount -LRB- SouthernBiotech , Birmingham , AL -RRB-	12120
@NP	Fluoromount	12120
@NP	SouthernBiotech	12133
@NP	Birmingham	12150
@NP	AL	12162
@NP	Quantification Methods	12184
@NP	the Injury Site Quantification	12210
@NP	Tissue Degeneration	12244
@NP	Every fifth section of the entire spinal cord	12264
@NP	Every fifth section	12264
@NP	the entire spinal cord	12287
@NP	100 µm	12323
@NP	Fibrous scar and cavities , a direct consequence of tissue degeneration ,	12360
@NP	Fibrous scar and cavities	12360
@NP	a direct consequence of tissue degeneration	12387
@NP	a direct consequence	12387
@NP	tissue degeneration	12411
@NP	GFAP negative	12436
@NP	GFAP	12436
@NP	the volume of GFAP-negative tissue	12483
@NP	the volume	12483
@NP	GFAP-negative tissue	12497
@NP	the injury site	12521
@NP	each GFAPlabeled section	12541
@NP	the lesion area	12567
@NP	a Leica microscope	12605
@NP	each section	12628
@NP	fibrous scar and cystic areas	12642
@NP	GFAP , negative tissue	12673
@NP	GFAP	12673
@NP	negative tissue	12679
@NP	square micrometers	12724
@NP	the image analysis program Metamorph , and volumes	12750
@NP	the image analysis program Metamorph	12750
@NP	the image analysis program	12750
@NP	Metamorph	12777
@NP	volumes	12792
@NP	as previously described -LRB- 28 , 29 -RRB-	12816
@NP	as previously	12816
@NP	28 , 29	12841
@NP	28	12841
@NP	29	12845
@NP	individual subvolumes	12859
@NP	the area in 1 section multiplied by the distance to the next -LRB- 100 µm -RRB-	12902
@NP	the area	12902
@NP	1 section multiplied by the distance to the next -LRB- 100 µm -RRB-	12914
@NP	1 section	12914
@NP	the distance	12938
@NP	the next -LRB- 100 µm -RRB-	12954
@NP	the next	12954
@NP	100 µm	12964
@NP	Quantification	12986
@NP	Axons Sections	13004
@NP	those	13031
@NP	the quantification of tissue degeneration	13046
@NP	the quantification	13046
@NP	tissue degeneration	13068
@NP	n = 28 , also separated by 100 µm	13089
@NP	n	13089
@NP	28	13093
@NP	100 µm	13115
@NP	anti-GFAP	13148
@NP	the borders	13168
@NP	the GFAP-positive glial scar	13183
@NP	anti-NFL	13221
@NP	axons	13240
@NP	Quantification	13247
@NP	the GFAP-negative fibrous scar	13278
@NP	the total number of pixels in this region determined by image analysis	13315
@NP	the total number	13315
@NP	pixels in this region determined by image analysis	13335
@NP	pixels	13335
@NP	this region determined by image analysis	13345
@NP	this region	13345
@NP	image analysis	13371
@NP	the percentages of those showing anti-NFL labeling	13387
@NP	the percentages	13387
@NP	those showing anti-NFL labeling	13406
@NP	those	13406
@NP	anti-NFL labeling	13420
@NP	The averages of the percentages per rat	13455
@NP	The averages	13455
@NP	the percentages per rat	13471
@NP	the percentages	13471
@NP	rat	13491
@NP	group comparisons	13509
@NP	Quantification	13528
@NP	Neuronal Regeneration Every fifth section of the whole brainstem	13546
@NP	Neuronal Regeneration	13546
@NP	Every fifth section of the whole brainstem	13568
@NP	Every fifth section	13568
@NP	the whole brainstem	13591
@NP	quantifying numbers of peroxidase-traced neurons	13624
@NP	quantifying numbers	13624
@NP	peroxidase-traced neurons	13647
@NP	sections	13682
@NP	order	13709
@NP	the precise location within the brainstem of each section	13716
@NP	the precise location	13716
@NP	the brainstem of each section	13744
@NP	the brainstem	13744
@NP	each section	13761
@NP	specific nuclei	13789
@NP	the Paxinos and Watson atlas -LRB- 30 -RRB-	13835
@NP	the Paxinos and Watson atlas	13835
@NP	30	13865
@NP	A distance between sections of 100 µm	13870
@NP	A distance	13870
@NP	sections of 100 µm	13889
@NP	sections	13889
@NP	100 µm	13901
@NP	double or triple counting of the same neuron	13916
@NP	double or triple counting	13916
@NP	the same neuron	13945
@NP	adjacent sections	13964
@NP	Peroxidase-containing somata	13983
@NP	their cytoplasmic brown diaminobenzidine chromogen reaction	14031
@NP	a Leica microscope	14109
@NP	Sections used for counting in each nucleus , and per rat	14129
@NP	Sections	14129
@NP	each nucleus	14159
@NP	rat	14181
@NP	red	14198
@NP	nucleus :	14202
@NP	nucleus	14202
@NP	14 -LRB- left -RRB-	14211
@NP	14 -LRB- right -RRB-	14225
@NP	reticular	14240
@NP	formation :	14250
@NP	formation	14250
@NP	66	14261
@NP	locus	14268
@NP	coeruleus : 20 -LRB- left -RRB-	14274
@NP	coeruleus	14274
@NP	20	14285
@NP	left	14289
@NP	and 20 -LRB- right -RRB-	14295
@NP	and 20	14295
@NP	right	14303
@NP	4 -RRB- vestibular nucleus : 26 -LRB- left -RRB- and 26 -LRB- right -RRB- ; 5	14311
@NP	vestibular	14314
@NP	nucleus :	14325
@NP	nucleus	14325
@NP	26 -LRB- left -RRB- and 26 -LRB- right -RRB- ; 5	14334
@NP	26 -LRB- left -RRB- and 26 -LRB- right -RRB-	14334
@NP	26 -LRB- left -RRB-	14334
@NP	26 -LRB- right -RRB-	14348
@NP	raphe nucleus : 60	14363
@NP	raphe nucleus	14363
@NP	60	14378
@NP	Images of sections	14382
@NP	Images	14382
@NP	sections	14392
@NP	10x magnification	14415
@NP	a camera -LRB- Leica DFC300 FX -RRB- attached to the microscope	14439
@NP	a camera -LRB- Leica DFC300 FX -RRB-	14439
@NP	a camera	14439
@NP	Leica DFC300 FX	14449
@NP	the microscope	14478
@NP	Statistical Analysis The variables of the behavioral recovery study	14494
@NP	Statistical Analysis The variables	14494
@NP	Statistical Analysis	14494
@NP	The variables	14515
@NP	the behavioral recovery study	14532
@NP	categories -LRB- 31 -RRB-	14575
@NP	categories	14575
@NP	31	14587
@NP	Each climbing grid	14592
@NP	Each	14592
@NP	grid	14606
@NP	an increasing angle from the horizontal plane	14625
@NP	an increasing angle	14625
@NP	the horizontal plane	14650
@NP	a higher slope	14686
@NP	the previous	14706
@NP	each slope	14724
@NP	1 level of difficulty for the animals -LRB- Appendix 1 -RRB-	14752
@NP	1 level	14752
@NP	difficulty for the animals -LRB- Appendix 1 -RRB-	14763
@NP	difficulty	14763
@NP	the animals -LRB- Appendix 1 -RRB-	14778
@NP	the animals	14778
@NP	Appendix 1	14791
@NP	Scores to each ordinal category or slope and named them climbing levels	14804
@NP	Scores	14804
@NP	each ordinal category or slope	14814
@NP	each ordinal category	14814
@NP	slope	14839
@NP	them	14855
@NP	levels	14869
@NP	1 < 2 < 3 < 4	14877
@NP	1 < 2 < 3 <	14877
@NP	1 < 2 <	14877
@NP	1 <	14877
@NP	4	14889
@NP	ordinal categories	14911
@NP	nonparametric Kruskal-Wallis and Mann-Whitney U tests	14931
@NP	32	15007
@NP	We	15012
@NP	the former test	15020
@NP	the ability of the Non-T , OEG-transplanted , and Sham groups	15047
@NP	the ability	15047
@NP	the Non-T , OEG-transplanted , and Sham groups	15062
@NP	the 4 different climbing levels	15116
@NP	both SA and Chr stages	15151
@NP	both SA	15151
@NP	Chr stages	15163
@NP	Post hoc Conover-Inman for pairwise comparison	15175
@NP	Post hoc Conover-Inman	15175
@NP	pairwise comparison	15202
@NP	33	15232
@NP	Mann-Whitney U test	15237
@NP	the climbing test of Non-T versus OEGtransplanted groups at SA and Chr stages	15303
@NP	the climbing test	15303
@NP	Non-T versus OEGtransplanted groups at SA and Chr stages	15324
@NP	Non-T	15324
@NP	OEGtransplanted groups at SA and Chr stages	15337
@NP	OEGtransplanted groups	15337
@NP	SA and Chr stages	15363
@NP	SA	15363
@NP	Chr stages	15370
@NP	Kruskal-Wallis test	15382
@NP	the significance of the time-dependent improvement	15423
@NP	the significance	15423
@NP	the time-dependent improvement	15443
@NP	function observed within the same group and between groups	15477
@NP	function	15477
@NP	the same group	15502
@NP	groups	15529
@NP	Statistical analyses	15537
@NP	differences	15561
@NP	groups	15581
@NP	the number of regenerated neurons -LRB- total and nuclei by nuclei -RRB-	15591
@NP	the number	15591
@NP	regenerated neurons -LRB- total and nuclei by nuclei -RRB-	15605
@NP	regenerated neurons	15605
@NP	total and nuclei by nuclei	15626
@NP	total and nuclei	15626
@NP	nuclei	15646
@NP	the extent of tissue degeneration at the injury site	15658
@NP	the extent	15658
@NP	tissue degeneration at the injury site	15672
@NP	tissue degeneration	15672
@NP	the injury site	15695
@NP	nonparametric Kruskal-Wallis and Mann-Whitney U tests	15729
@NP	Nonparametric statistics	15784
@NP	the experimental groups	15827
@NP	fewer than 10 animals	15855
@NP	Data	15878
@NP	the mean T SEM	15900
@NP	all cases	15919
@NP	differences	15930
@NP	p	15973
@NP	Linear regression analysis	15983
@NP	the correlation between functional recovery and the number of neurons	16031
@NP	the correlation between functional recovery	16031
@NP	the correlation	16031
@NP	functional recovery	16055
@NP	the number of neurons	16079
@NP	the number	16079
@NP	neurons	16093
@NP	axons	16114
@NP	individual animals	16125
@NP	an estimation of the temporary progression of the functional recovery per rat	16149
@NP	an estimation	16149
@NP	the temporary progression of the functional recovery per rat	16166
@NP	the temporary progression	16166
@NP	the functional recovery per rat	16195
@NP	the functional recovery	16195
@NP	rat	16223
@NP	a score for each animal	16228
@NP	a score	16228
@NP	each animal	16240
@NP	the level achieved in the climbing test at each month during the testing period	16278
@NP	the level	16278
@NP	the climbing test at each month during the testing period	16300
@NP	the climbing test	16300
@NP	each month during the testing period	16321
@NP	each month	16321
@NP	the testing period	16339
@NP	These scores	16359
@NP	linear regression	16396
@NP	the number of regenerated neurons	16419
@NP	the number	16419
@NP	regenerated neurons	16433
@NP	individual animals	16458
@NP	RESULTS	16479
@NP	Brainstem Neurons Traced in Transplanted and Nontransplanted Animals	16494
@NP	Brainstem Neurons Traced	16494
@NP	Transplanted and Nontransplanted Animals	16522
@NP	1	16571
@NP	Appearance of the surgical field during different phases of the procedure .	16574
@NP	Appearance	16574
@NP	the surgical field during different phases	16588
@NP	the surgical field	16588
@NP	different phases	16614
@NP	the procedure	16634
@NP	-LRB- A -RRB- After spinal cord transection , both stumps	16649
@NP	-LRB- A -RRB-	16649
@NP	spinal cord transection	16659
@NP	stumps	16689
@NP	completeness of the lesion	16718
@NP	completeness	16718
@NP	the lesion	16734
@NP	-LRB- B -RRB- Spinal cord stumps	16746
@NP	-LRB- B -RRB- Spinal cord	16746
@NP	B	16747
@NP	the vertebral channel apposing one another	16791
@NP	the vertebral channel	16791
@NP	one another	16822
@NP	-LRB- C-F -RRB-	16835
@NP	Lesion region	16841
@NP	the second surgery -LRB- access to the spinal cord for transplantation -RRB-	16862
@NP	the second surgery	16862
@NP	access to the spinal cord for transplantation	16882
@NP	access	16882
@NP	the spinal cord for transplantation	16892
@NP	the spinal cord	16892
@NP	transplantation	16912
@NP	-LRB- C -RRB- The resin bridge -LRB- arrow -RRB-	16930
@NP	-LRB- C -RRB- The resin bridge	16930
@NP	-LRB- C -RRB-	16930
@NP	The resin bridge	16934
@NP	arrow	16952
@NP	the spinous processes and laminae of adjacent intact vertebrae	16979
@NP	the spinous processes and laminae	16979
@NP	adjacent intact vertebrae	17016
@NP	bridge removal	17053
@NP	a dense layer of connective tissue -LRB- arrowheads -RRB-	17069
@NP	a dense layer	17069
@NP	connective tissue -LRB- arrowheads -RRB-	17086
@NP	connective tissue	17086
@NP	arrowheads	17105
@NP	the underlying spinal cord -LRB- arrow -RRB-	17139
@NP	the underlying spinal cord	17139
@NP	arrow	17167
@NP	-LRB- E -RRB-	17175
@NP	Dorsal aspect of both spinal cord stumps	17179
@NP	Dorsal aspect	17179
@NP	both spinal cord stumps	17196
@NP	4 months after complete transection	17220
@NP	4 months	17220
@NP	complete transection	17235
@NP	-LRB- F -RRB- Transplantation of olfactory bulb	17257
@NP	-LRB- F -RRB-	17257
@NP	olfactory bulb	17280
@NP	ensheathing glia -LRB- OB-OEG -RRB- using a glass microneedle	17295
@NP	ensheathing glia -LRB- OB-OEG -RRB-	17295
@NP	ensheathing glia	17295
@NP	OB-OEG	17313
@NP	a glass microneedle	17327
@NP	arrow	17348
@NP	Inset	17356
@NP	a detail	17363
@NP	an OB-OEG culture used for transplantation and immunolabeled with anti-p75	17375
@NP	an OB-OEG culture	17375
@NP	transplantation	17402
@NP	anti-p75	17441
@NP	Arrows in -LRB- A -RRB- , -LRB- B -RRB- , and -LRB- E -RRB-	17451
@NP	Arrows	17451
@NP	-LRB- A -RRB- , -LRB- B -RRB- , and -LRB- E -RRB-	17461
@NP	-LRB- A -RRB-	17461
@NP	-LRB- B -RRB-	17466
@NP	-LRB- E -RRB-	17475
@NP	the transection sites	17488
@NP	FIGURE 2 .	17512
@NP	FIGURE	17512
@NP	2	17519
@NP	Video frames	17522
@NP	a paraplegic rat	17538
@NP	olfactory bulb ensheathing glia at the chronic stage	17573
@NP	olfactory bulb ensheathing glia	17573
@NP	the chronic stage	17608
@NP	the third climbing level , 5 months	17637
@NP	the third	17637
@NP	level	17656
@NP	5 months	17663
@NP	transplantation	17678
@NP	Detail of the hindlimb movement	17695
@NP	Detail	17695
@NP	the hindlimb movement	17705
@NP	this rat	17742
@NP	its weight	17760
@NP	its body to reach the horizontal platform	17783
@NP	the horizontal platform	17801
@NP	The video of this animal	17826
@NP	The video	17826
@NP	this animal	17839
@NP	part of Video , Supplemental Digital Content 1 , http://links.lww.com/NEN/A62	17854
@NP	part	17854
@NP	Video , Supplemental Digital Content 1 , http://links.lww.com/NEN/A62	17862
@NP	Video , Supplemental Digital Content 1	17862
@NP	http://links.lww.com/NEN/A62	17901
@NP	FIGURE 3 .	17932
@NP	FIGURE	17932
@NP	3	17939
@NP	Functional recovery	17942
@NP	paraplegic rats	17965
@NP	olfactory bulb ensheathing glia transplantation at subacute -LRB- SA -RRB-	17987
@NP	olfactory bulb ensheathing glia transplantation	17987
@NP	subacute -LRB- SA -RRB-	18038
@NP	subacute	18038
@NP	SA	18048
@NP	chronic -LRB- Chr -RRB- stages	18056
@NP	Chr	18065
@NP	-LRB- A , B -RRB- Levels	18078
@NP	the climbing test	18104
@NP	-LRB- A -RRB- nontransplanted -LRB- Non-T -RRB- and SA	18125
@NP	-LRB- A -RRB- nontransplanted -LRB- Non-T -RRB-	18125
@NP	-LRB- A -RRB- nontransplanted	18125
@NP	-LRB- A -RRB-	18125
@NP	Non-T	18146
@NP	SA	18157
@NP	-LRB- B -RRB- Non-T	18168
@NP	B	18169
@NP	Chr rats at 3 , 5 , and 7 months postgrafting	18182
@NP	Chr rats	18182
@NP	3 , 5 , and 7 months	18194
@NP	3	18194
@NP	5	18197
@NP	7 months	18204
@NP	rats	18240
@NP	a functional recovery significantly higher	18252
@NP	a functional recovery	18252
@NP	that of Non-T -LRB- SA , p G 0.001 ; Chr , p = 0.001 -RRB-	18300
@NP	that	18300
@NP	Non-T -LRB- SA , p G 0.001 ; Chr , p = 0.001 -RRB-	18308
@NP	Non-T	18308
@NP	SA , p G 0.001 ; Chr , p = 0.001	18315
@NP	SA	18315
@NP	p G 0.001 ; Chr , p = 0.001	18319
@NP	p G 0.001	18319
@NP	p G	18319
@NP	0.001	18323
@NP	Chr , p = 0.001	18330
@NP	Chr	18330
@NP	p = 0.001	18335
@NP	p	18335
@NP	0.001	18339
@NP	Differences	18347
@NP	Month 6	18390
@NP	SA rats -LRB- Month 6 , p = 0.029 ; Months 7 and 8 , p = 0.020 -RRB-	18401
@NP	SA rats	18401
@NP	Month 6 , p = 0.029 ; Months 7 and 8 , p = 0.020	18410
@NP	Month 6	18410
@NP	p = 0.029 ; Months 7 and 8 , p = 0.020	18419
@NP	p = 0.029	18419
@NP	p	18419
@NP	0.029	18423
@NP	Months 7 and 8 , p = 0.020	18430
@NP	Months 7 and 8	18430
@NP	p = 0.020	18446
@NP	p	18446
@NP	0.020	18450
@NP	Month 7	18466
@NP	Chr -LRB- p = 0.045 -RRB-	18477
@NP	Chr	18477
@NP	p	18482
@NP	0.045	18486
@NP	There	18494
@NP	no differences	18505
@NP	SA and Chr groups -LRB- compare -LSB- A -RSB- and -LSB- B -RSB- -RRB-	18528
@NP	SA and Chr groups	18528
@NP	SA	18528
@NP	Chr groups	18535
@NP	A -RSB- and -LSB- B -RSB-	18556
@NP	A -RSB-	18556
@NP	-LSB- B -RSB-	18563
@NP	Progression	18573
@NP	the functional outcome in all groups	18588
@NP	the functional outcome	18588
@NP	all groups	18614
@NP	the first month postlesion	18630
@NP	the end of the survival period -LRB- Month 12 -RRB-	18663
@NP	the end	18663
@NP	the survival period -LRB- Month 12 -RRB-	18674
@NP	the survival period	18674
@NP	Month 12	18695
@NP	Each point	18706
@NP	the percentage of functional recovery	18728
@NP	the percentage	18728
@NP	functional recovery	18746
@NP	animals of each group	18779
@NP	animals	18779
@NP	each group	18790
@NP	lines	18809
@NP	the periods	18820
@NP	the outcome	18848
@NP	Non-T versus SA -LRB- long dash -RRB-	18863
@NP	Non-T	18863
@NP	SA -LRB- long dash -RRB-	18876
@NP	SA	18876
@NP	long dash	18880
@NP	Non-T versus Chr animals -LRB- short dash -RRB-	18895
@NP	Non-T	18895
@NP	Chr animals -LRB- short dash -RRB-	18908
@NP	Chr animals	18908
@NP	short dash	18921
@NP	the first	18938
@NP	the eighth month postgrafting	18951
@NP	The Non-T animals -LRB- gray rhombi -RRB-	18982
@NP	The Non-T animals	18982
@NP	gray rhombi	19001
@NP	a slight but insignificant recovery	19021
@NP	Chr and SA groups	19075
@NP	Non-T animals	19104
@NP	The SA group -LRB- black circles -RRB- and Chr -LRB- black triangles -RRB-	19119
@NP	The SA group -LRB- black circles -RRB-	19119
@NP	The SA group	19119
@NP	black circles	19133
@NP	Chr -LRB- black triangles -RRB-	19152
@NP	Chr	19152
@NP	black triangles	19157
@NP	2 months	19192
@NP	transplantation	19207
@NP	3 and 6 months postlesion , respectively	19224
@NP	3 and 6 months postlesion	19224
@NP	3 and 6 months	19224
@NP	postlesion	19239
@NP	Improvement of SA and Chr rats	19266
@NP	Improvement	19266
@NP	SA and Chr rats	19281
@NP	SA	19281
@NP	Chr rats	19288
@NP	the second month	19310
@NP	the fifth -LRB- p = 0.004 -RRB- and fourth months -LRB- p = 0.021 -RRB-	19360
@NP	the fifth	19360
@NP	p	19371
@NP	0.004	19375
@NP	fourth months	19386
@NP	p	19401
@NP	0.021	19405
@NP	FIGURE 4 .	19428
@NP	FIGURE	19428
@NP	4	19435
@NP	Transection sites of olfactory bulb	19438
@NP	Transection sites	19438
@NP	olfactory bulb	19459
@NP	gliaYgrafted	19486
@NP	nontransplanted -LRB- Non-T -RRB- spinal cords	19503
@NP	Non-T	19520
@NP	12 months	19540
@NP	lesion	19556
@NP	Representative macroscopic images	19564
@NP	subacute -LRB- SA -RRB- -LRB- A -RRB-	19603
@NP	subacute -LRB- SA -RRB-	19603
@NP	subacute	19603
@NP	SA	19613
@NP	A	19618
@NP	chronic -LRB- Chr -RRB- -LRB- B -RRB- transplanted spinal cords	19625
@NP	chronic -LRB- Chr -RRB- -LRB- B -RRB-	19625
@NP	chronic -LRB- Chr -RRB-	19625
@NP	B	19640
@NP	spinal cords	19656
@NP	a Non-T spinal cord -LRB- C -RRB-	19678
@NP	a Non-T spinal cord	19678
@NP	C	19699
@NP	Rostral and caudal stumps in all transplanted cords	19703
@NP	Rostral and caudal stumps	19703
@NP	all transplanted cords	19732
@NP	white opaque tissue -LRB- A , B -RRB-	19771
@NP	white opaque tissue	19771
@NP	A , B	19792
@NP	A	19792
@NP	B	19795
@NP	cord stumps in Non-T rats	19799
@NP	cord stumps	19799
@NP	Non-T rats	19814
@NP	a translucent membrane -LRB- C -RRB-	19840
@NP	a translucent membrane	19840
@NP	C	19864
@NP	FIGURE 5 .	19869
@NP	FIGURE	19869
@NP	5	19876
@NP	Longitudinal spinal cord sections	19879
@NP	areas	19921
@NP	quantification of glial fibrillary acidic protein -LRB- GFAP -RRB-	19936
@NP	quantification	19936
@NP	glial fibrillary acidic protein -LRB- GFAP -RRB-	19954
@NP	glial fibrillary acidic protein	19954
@NP	GFAP	19987
@NP	negative tissue at the injury site	19993
@NP	negative tissue	19993
@NP	the injury site	20012
@NP	Sections of nontransplanted -LRB- A -RRB- and transplanted -LRB- B -RRB-	20029
@NP	Sections	20029
@NP	nontransplanted -LRB- A -RRB- and transplanted -LRB- B -RRB-	20041
@NP	nontransplanted -LRB- A -RRB-	20041
@NP	transplanted -LRB- B -RRB-	20065
@NP	transplanted	20065
@NP	B	20079
@NP	spinal cords immunolabeled with anti-GFAP	20082
@NP	spinal cords	20082
@NP	anti-GFAP	20114
@NP	Encircled lines	20125
@NP	GFAP-negative fibrous scar -LRB- arrows -RRB-	20156
@NP	GFAP-negative fibrous scar	20156
@NP	arrows	20184
@NP	cysts -LRB- without arrows -RRB-	20196
@NP	cysts	20196
@NP	arrows	20211
@NP	The widths of the cords	20220
@NP	The widths	20220
@NP	the cords	20234
@NP	these sections -LRB- horizontal lines in -LSB- A -RSB- and -LSB- B -RSB- -RRB-	20266
@NP	these sections	20266
@NP	horizontal lines in -LSB- A -RSB- and -LSB- B -RSB-	20282
@NP	horizontal lines	20282
@NP	-LSB- A -RSB- and -LSB- B -RSB-	20302
@NP	Top , rostral ; bottom , caudal .	20316
@NP	Top , rostral	20316
@NP	Top	20316
@NP	rostral	20321
@NP	bottom , caudal	20330
@NP	bottom	20330
@NP	caudal	20338
@NP	FIGURE 6 .	20347
@NP	FIGURE	20347
@NP	6	20354
@NP	Brainstem coronal sections	20357
@NP	peroxidase-traced neurons	20392
@NP	olfactory bulb ensheathing glia -LRB- OB-OEG -RRB-	20421
@NP	olfactory bulb ensheathing glia	20421
@NP	OB-OEG	20454
@NP	transplanted -LRB- A , C , E , G , I -RRB-	20462
@NP	transplanted	20462
@NP	A	20476
@NP	C , E , G	20479
@NP	I	20488
@NP	nontransplanted -LRB- B , D , F , H , J -RRB- rats	20495
@NP	B , D , F , H , J	20512
@NP	B	20512
@NP	D	20515
@NP	F	20518
@NP	H	20521
@NP	J	20524
@NP	-LRB- A , B -RRB- Reticular formation -LRB- RF -RRB- .	20533
@NP	-LRB- A , B -RRB- Reticular formation -LRB- RF -RRB-	20533
@NP	-LRB- A , B -RRB- Reticular formation	20533
@NP	A , B	20534
@NP	A	20534
@NP	B	20537
@NP	RF	20561
@NP	-LRB- C , D -RRB- Vestibular nucleus -LRB- VN -RRB- .	20566
@NP	-LRB- C , D -RRB- Vestibular nucleus -LRB- VN -RRB-	20566
@NP	-LRB- C , D -RRB- Vestibular nucleus	20566
@NP	VN	20593
@NP	-LRB- E , F -RRB-	20598
@NP	E , F	20599
@NP	E	20599
@NP	F	20602
@NP	coeruleus -LRB- LC -RRB-	20611
@NP	coeruleus	20611
@NP	LC	20622
@NP	-LRB- G , H -RRB-	20627
@NP	R	20641
@NP	-LRB- I , J -RRB- Red nucleus -LRB- RN -RRB- .	20645
@NP	-LRB- I , J -RRB- Red nucleus -LRB- RN -RRB-	20645
@NP	-LRB- I , J -RRB- Red nucleus	20645
@NP	I	20646
@NP	J	20649
@NP	RN	20665
@NP	Scale	20670
@NP	= -LRB- A-J -RRB- 50 µm	20680
@NP	= -LRB- A-J -RRB-	20680
@NP	50 µm	20688
@NP	Top , dorsal ; bottom , ventral .	20695
@NP	Top , dorsal	20695
@NP	Top	20695
@NP	dorsal	20700
@NP	bottom , ventral	20708
@NP	bottom	20708
@NP	ventral	20716
@NP	FIGURE 7 .	20726
@NP	FIGURE	20726
@NP	7	20733
@NP	Quantification of neurons regenerating axons beyond the injury region .	20736
@NP	Quantification of neurons	20736
@NP	Quantification	20736
@NP	neurons	20754
@NP	axons	20775
@NP	the injury region	20788
@NP	A-E	20808
@NP	Histograms	20813
@NP	the number of peroxidase-traced neurons in nontransplanted -LRB- Non-T -RRB-	20829
@NP	the number	20829
@NP	peroxidase-traced neurons in nontransplanted -LRB- Non-T -RRB-	20843
@NP	peroxidase-traced neurons	20843
@NP	nontransplanted -LRB- Non-T -RRB-	20872
@NP	nontransplanted	20872
@NP	Non-T	20889
@NP	subacute -LRB- SA -RRB- , chronic -LRB- Chr -RRB- , and sham groups	20897
@NP	subacute -LRB- SA -RRB- , chronic -LRB- Chr -RRB- ,	20897
@NP	subacute -LRB- SA -RRB-	20897
@NP	subacute	20897
@NP	SA	20907
@NP	chronic -LRB- Chr -RRB-	20912
@NP	sham groups	20931
@NP	raphe -LRB- A -RRB-	20954
@NP	raphe	20954
@NP	A	20961
@NP	reticular formation -LRB- B -RRB-	20965
@NP	reticular formation	20965
@NP	B	20986
@NP	vestibular nuclei -LRB- C -RRB-	20990
@NP	vestibular nuclei	20990
@NP	C	21009
@NP	locus coeruleus -LRB- D -RRB-	21013
@NP	locus coeruleus	21013
@NP	D	21030
@NP	red nuclei -LRB- E -RRB-	21034
@NP	red nuclei	21034
@NP	E	21046
@NP	all nuclei -LRB- F -RRB-	21057
@NP	all nuclei	21057
@NP	F	21069
@NP	Black rhombi	21073
@NP	the number of cell bodies per animal	21096
@NP	the number	21096
@NP	cell bodies per animal	21110
@NP	cell bodies	21110
@NP	animal	21126
@NP	bars	21134
@NP	the average of cell bodies per group	21143
@NP	the average	21143
@NP	cell bodies per group	21158
@NP	cell bodies	21158
@NP	group	21174
@NP	The total number of traced neurons	21181
@NP	The total number	21181
@NP	traced neurons	21201
@NP	SA	21244
@NP	Chr animals	21251
@NP	that	21268
@NP	Non-T	21276
@NP	nuclei -LRB- except for raphe in SA rats -RRB- -LRB- p < 0.05 -RRB-	21310
@NP	nuclei -LRB- except for raphe in SA rats -RRB-	21310
@NP	nuclei	21310
@NP	raphe in SA rats	21329
@NP	raphe	21329
@NP	SA rats	21338
@NP	p < 0.05	21348
@NP	p	21348
@NP	< 0.05	21350
@NP	<	21350
@NP	0.05	21352
@NP	There	21359
@NP	no significant differences between SA and Chr groups in any case	21370
@NP	no significant differences between SA	21370
@NP	no significant differences	21370
@NP	SA	21405
@NP	Chr groups in any case	21412
@NP	Chr groups	21412
@NP	any case	21426
@NP	All animals	21437
@NP	injury	21464
@NP	the following 2 surgeries -LRB- transplantation and tracer injection -RRB-	21481
@NP	the following 2 surgeries	21481
@NP	transplantation and tracer injection	21508
@NP	1 Non-T rat that died during the second surgery -LRB- DMEM injection -RRB-	21558
@NP	1 Non-T rat	21558
@NP	the second surgery -LRB- DMEM injection -RRB-	21587
@NP	the second surgery	21587
@NP	DMEM injection	21607
@NP	4 more Non-T rats	21624
@NP	1 , 1.5 , 2 , and 4 months	21650
@NP	1	21650
@NP	1.5	21653
@NP	2	21658
@NP	4 months	21665
@NP	the second surgery	21680
@NP	autonomic dysreflexia or unknown causes	21710
@NP	autonomic dysreflexia	21710
@NP	unknown causes	21735
@NP	One Non-T rat	21751
@NP	the study	21785
@NP	it	21803
@NP	autotomy of its hindlimb	21816
@NP	autotomy	21816
@NP	its hindlimb	21828
@NP	6 rats	21848
@NP	Non-T controls	21868
@NP	none of the OB-OEG-grafted rats	21896
@NP	none	21896
@NP	the OB-OEG-grafted rats	21904
@NP	any complication	21932
@NP	1 animal	21958
@NP	the Chr group	21972
@NP	the very end of the study -LRB- 11.5 months after injury -RRB-	21994
@NP	the very end	21994
@NP	the study -LRB- 11.5 months after injury -RRB-	22010
@NP	the study	22010
@NP	11.5 months after injury	22021
@NP	11.5 months	22021
@NP	injury	22039
@NP	OB-OEG Transplantation	22048
@NP	Voluntary Hindlimb Movement All	22080
@NP	transplanted and Non-T SCI rats	22112
@NP	transplanted	22112
@NP	Non-T SCI rats	22129
@NP	flaccid hindlimb paralysis	22148
@NP	We	22176
@NP	the climbing ability of all animals	22195
@NP	the climbing ability	22195
@NP	all animals	22219
@NP	1 month	22231
@NP	lesion	22245
@NP	the whole period	22260
@NP	Non-T rats of either group -LRB- second surgery after 1 or 4 months -RRB-	22278
@NP	Non-T rats	22278
@NP	either group -LRB- second surgery after 1 or 4 months -RRB-	22292
@NP	either group	22292
@NP	second surgery after 1 or 4 months	22306
@NP	second surgery	22306
@NP	1 or 4 months	22327
@NP	any difference in performance -LRB- p = 0.794 and p = 0.770 , respectively -RRB-	22355
@NP	any difference	22355
@NP	performance -LRB- p = 0.794 and p = 0.770 , respectively -RRB-	22373
@NP	performance	22373
@NP	p = 0.794 and p = 0.770 , respectively	22386
@NP	p = 0.794	22386
@NP	p	22386
@NP	0.794	22390
@NP	p = 0.770 , respectively	22400
@NP	p	22400
@NP	= 0.770	22402
@NP	This	22426
@NP	agreement with previous studies	22437
@NP	agreement	22437
@NP	previous studies	22452
@NP	the absence of histological differences	22477
@NP	the absence	22477
@NP	histological differences	22492
@NP	culture medium injection -LRB- 10 -RRB-	22523
@NP	culture medium injection	22523
@NP	10	22549
@NP	addition	22557
@NP	this	22567
@NP	the second surgery and our injection protocol	22587
@NP	the second surgery	22587
@NP	our injection protocol	22610
@NP	the normal progression of tissue changes	22675
@NP	the normal progression	22675
@NP	tissue changes	22701
@NP	all paraplegic Non-T rats	22725
@NP	they	22785
@NP	a single group -LRB- n = 6 -RRB-	22809
@NP	a single group	22809
@NP	n	22825
@NP	6	22829
@NP	Rats from both SA and Chr groups	22833
@NP	Rats	22833
@NP	both SA and Chr groups	22843
@NP	both SA	22843
@NP	Chr groups	22855
@NP	Non-T rats	22877
@NP	the climbing test before transplantation	22891
@NP	the climbing test	22891
@NP	transplantation	22916
@NP	We	22933
@NP	the climbing behavior	22954
@NP	OB-OEG-grafted and nongrafted rats	22979
@NP	the first month postgrafting	23019
@NP	the second month postlesion for the SA group and the fifth for the Chr group	23070
@NP	the second month postlesion for the SA group	23070
@NP	the second month postlesion	23070
@NP	the SA group	23102
@NP	the fifth for the Chr group	23119
@NP	the Chr	23133
@NP	Fig. 3C	23148
@NP	Functional Recovery	23158
@NP	the Subacute Stage All	23196
@NP	SA-transplanted rats	23219
@NP	the	23264
@NP	test -LRB- Fig. 3A -RRB-	23277
@NP	test	23277
@NP	Fig. 3A	23283
@NP	There	23293
@NP	a significant functional improvement	23303
@NP	SA group	23343
@NP	the ability to climb compared with the Non-T group -LRB- p < 0.001 -RRB-	23355
@NP	the Non-T group -LRB- p < 0.001 -RRB-	23390
@NP	the Non-T group	23390
@NP	p < 0.001	23407
@NP	p	23407
@NP	< 0.001	23409
@NP	<	23409
@NP	0.001	23411
@NP	The OB-OEG-grafted rats	23419
@NP	a progressive improvement	23450
@NP	abilities	23488
@NP	the second month	23507
@NP	transplantation , differences between SA and Non-T rats	23530
@NP	transplantation	23530
@NP	differences between SA and Non-T rats	23547
@NP	differences	23547
@NP	SA and Non-T rats	23567
@NP	this time	23604
@NP	2 -LRB- 40 % -RRB- of 5 SA rats	23615
@NP	2 -LRB- 40 % -RRB-	23615
@NP	2	23615
@NP	40 %	23618
@NP	5 SA rats	23626
@NP	Level 1	23645
@NP	a month later	23654
@NP	one of these rats	23669
@NP	one	23669
@NP	these rats	23676
@NP	Level 2 and a third reached Level 1	23702
@NP	Level 2	23702
@NP	a third reached Level 1	23714
@NP	a third	23714
@NP	Level 1	23730
@NP	5 months postgrafting	23742
@NP	5 months	23742
@NP	all SA rats	23765
@NP	the climbing test	23790
@NP	1 achieved Level 3 and 4 -LRB- 80 % -RRB-	23809
@NP	1	23809
@NP	Level 3 and 4 -LRB- 80 % -RRB-	23820
@NP	Level 3 and 4	23820
@NP	80 %	23835
@NP	Level 1	23848
@NP	comparison	23860
@NP	half of Non-T rats -LRB- 50 % -RRB-	23872
@NP	half	23872
@NP	Non-T rats -LRB- 50 % -RRB-	23880
@NP	Non-T rats	23880
@NP	50 %	23892
@NP	any	23915
@NP	level	23928
@NP	the remaining	23944
@NP	some spontaneous improvement	23968
@NP	the recovery of Non-T rats	23998
@NP	the recovery	23998
@NP	Non-T rats	24014
@NP	that of transplanted animals	24049
@NP	that	24049
@NP	transplanted animals	24057
@NP	Only 1 of 6 Non-T rats	24079
@NP	Only 1	24079
@NP	6 Non-T rats	24089
@NP	Level 1	24111
@NP	the second month postinjury	24122
@NP	the only rat that improved thereafter	24158
@NP	the only rat	24158
@NP	the fourth and fifth months	24203
@NP	another 2 rats	24246
@NP	the lowest climbing level	24270
@NP	no further improvement -LRB- Fig. 3A -RRB-	24306
@NP	no further improvement	24306
@NP	Fig. 3A	24330
@NP	comparison	24343
@NP	SA animals	24355
@NP	significantly better scores in the climbing test	24373
@NP	significantly better scores	24373
@NP	the climbing test	24404
@NP	function	24446
@NP	the fifth month	24461
@NP	7 months after OB-OEG transplantation	24481
@NP	7 months	24481
@NP	OB-OEG transplantation	24496
@NP	SA rats	24520
@NP	their maximum functional recovery	24536
@NP	4 of them -LRB- 80 % -RRB-	24571
@NP	4 of them	24571
@NP	4	24571
@NP	them	24576
@NP	80 %	24582
@NP	Level 3 and one achieved Level 2 -LRB- Fig. 3A -RRB-	24597
@NP	Level 3 and one	24597
@NP	Level 2 -LRB- Fig. 3A -RRB-	24622
@NP	Level 2	24622
@NP	Fig. 3A	24631
@NP	A monthly comparison of functional outcome	24641
@NP	A monthly comparison	24641
@NP	functional outcome	24665
@NP	significant differences between SA and Non-T groups from the sixth month	24691
@NP	significant differences between SA	24691
@NP	significant differences	24691
@NP	SA	24723
@NP	Non-T groups from the sixth month	24730
@NP	Non-T groups	24730
@NP	the sixth month	24748
@NP	transplantation	24770
@NP	the end of the experiment	24792
@NP	the end	24792
@NP	the experiment	24803
@NP	Conover-Inman	24819
@NP	hoc	24838
@NP	values	24842
@NP	p =	24854
@NP	0.0145	24858
@NP	the sixth month and p = 0.0095	24868
@NP	the sixth month and p	24868
@NP	0.0095	24892
@NP	the seventh month	24902
@NP	Mann-Whitney U test	24921
@NP	a significance of p	24953
@NP	a significance	24953
@NP	p	24971
@NP	0.029	24975
@NP	Month 6	24984
@NP	p	24996
@NP	0.020	25000
@NP	Month 7	25009
@NP	the fifth month postgrafting	25034
@NP	the climbing performance exhibited by OB-OEG transplanted rats	25064
@NP	the climbing performance	25064
@NP	OB-OEG transplanted rats	25102
@NP	the first -LRB- p = 0.004 -RRB- and second months -LRB- p = 0.042 -RRB-	25146
@NP	the first	25146
@NP	p	25157
@NP	0.004	25161
@NP	second months	25172
@NP	p	25187
@NP	0.042	25191
@NP	This time-dependent recovery	25199
@NP	the seventh month	25252
@NP	Climbing performance at the seventh month	25271
@NP	Climbing performance	25271
@NP	the seventh month	25295
@NP	that	25343
@NP	first -LRB- p = 0.004 -RRB-	25351
@NP	first	25351
@NP	p	25358
@NP	0.004	25362
@NP	second -LRB- p = 0.006 -RRB-	25370
@NP	second	25370
@NP	p	25378
@NP	0.006	25382
@NP	third and fourth months -LRB- p = 0.009 , both -RRB-	25394
@NP	third and fourth months	25394
@NP	p = 0.009 , both	25419
@NP	p = 0.009	25419
@NP	p	25419
@NP	0.009	25423
@NP	comparison	25440
@NP	Non-T animals	25452
@NP	their climbing abilities	25482
@NP	time	25512
@NP	the spontaneous outcome exhibited by some of them	25522
@NP	the spontaneous outcome	25522
@NP	some of them	25559
@NP	some	25559
@NP	them	25567
@NP	statistical significance	25585
@NP	Functional Recovery	25611
@NP	the Chronic Stage	25649
@NP	transplantation	25674
@NP	Chr rats	25691
@NP	the climbing test similar to Non-T rats	25711
@NP	the climbing test	25711
@NP	Non-T rats	25740
@NP	transplantation -LRB- 4 months after injury -RRB-	25762
@NP	transplantation	25762
@NP	4 months after injury	25779
@NP	4 months	25779
@NP	injury	25794
@NP	they	25803
@NP	function more	25818
@NP	Non-T rats -LRB- p = 0.002 -RRB-	25837
@NP	Non-T rats	25837
@NP	p	25849
@NP	0.002	25853
@NP	One Non-T and 2 Chr rats	25861
@NP	One Non-T	25861
@NP	2 Chr rats	25875
@NP	some spontaneous recovery	25893
@NP	the second surgery -LRB- 4 months postlesion -RRB-	25931
@NP	the second surgery	25931
@NP	4 months postlesion	25951
@NP	4 months	25951
@NP	postlesion	25960
@NP	the lowest climbing level -LRB- not shown -RRB-	25985
@NP	the lowest climbing level	25985
@NP	The functional capabilities of the 2 Chr rats showing some recovery	26024
@NP	The functional capabilities	26024
@NP	the 2 Chr rats showing some recovery	26055
@NP	the 2 Chr rats	26055
@NP	some recovery	26078
@NP	OB-OEG injection	26118
@NP	proper integration of the graft within the cord parenchyma	26147
@NP	proper integration	26147
@NP	the graft within the cord parenchyma	26169
@NP	the graft	26169
@NP	the cord parenchyma	26186
@NP	the transplantation	26226
@NP	a chronic SCI	26276
@NP	The Chr rats	26291
@NP	motor function	26313
@NP	Non-T rats -LRB- p = 0.002 -RRB-	26352
@NP	Non-T rats	26352
@NP	p	26364
@NP	0.002	26368
@NP	improvement	26380
@NP	progressive -LRB- p = 0.016 -RRB- -LRB- Fig. 3B -RRB-	26396
@NP	progressive -LRB- p = 0.016 -RRB-	26396
@NP	progressive	26396
@NP	p	26409
@NP	0.016	26413
@NP	Fig. 3B	26421
@NP	The Chr rats	26431
@NP	motor function 2 months -LRB- 6 postlesion -RRB-	26457
@NP	motor function 2 months	26457
@NP	motor function	26457
@NP	2 months	26472
@NP	6 postlesion	26482
@NP	this period	26515
@NP	3 rats	26528
@NP	Level 1	26544
@NP	a month later	26557
@NP	they	26572
@NP	Level 2 or 3	26593
@NP	All Chr rats	26607
@NP	at least Level	26639
@NP	1 at 4 months	26654
@NP	grafting	26674
@NP	the fifth month	26687
@NP	3 of 5 rats	26704
@NP	3	26704
@NP	5 rats	26709
@NP	Level 3 , 1	26725
@NP	Level 2 , and the other , Level 1	26745
@NP	Level 2	26745
@NP	the other , Level 1	26758
@NP	the other	26758
@NP	Level 1	26769
@NP	These animals	26778
@NP	their maximum functional recovery	26799
@NP	the seventh month	26839
@NP	this	26862
@NP	the maximum	26900
@NP	performance	26921
@NP	Non-T rats	26945
@NP	Conover-Inman , p = 0.0299 ; Mann-Whitney U test , p = 0.045	26957
@NP	Conover-Inman	26957
@NP	p = 0.0299 ; Mann-Whitney U test , p = 0.045	26972
@NP	p = 0.0299	26972
@NP	p	26972
@NP	0.0299	26976
@NP	Mann-Whitney U test , p = 0.045	26984
@NP	Mann-Whitney U test	26984
@NP	p = 0.045	27005
@NP	p	27005
@NP	0.045	27009
@NP	The recovery level of the Chr rats	27017
@NP	The recovery level	27017
@NP	the Chr rats	27039
@NP	4 months	27066
@NP	at 1 -LRB- p = 0.021 -RRB- and 2 months -LRB- p = 0.033 -RRB-	27093
@NP	at 1 -LRB- p = 0.021 -RRB-	27093
@NP	at 1	27093
@NP	p	27099
@NP	0.021	27103
@NP	2 months -LRB- p = 0.033 -RRB-	27114
@NP	p	27124
@NP	0.033	27128
@NP	These differences	27136
@NP	the seventh month -LRB- p = 0.013 vs Month 1 ; p = 0.016 vs Month 2 -RRB-	27200
@NP	the seventh month	27200
@NP	p = 0.013 vs Month 1 ; p = 0.016 vs Month 2	27219
@NP	p	27219
@NP	= 0.013 vs Month 1 ; p = 0.016 vs Month 2	27221
@NP	= 0.013 vs Month 1	27221
@NP	= 0.013	27221
@NP	Month 1	27232
@NP	p = 0.016 vs Month 2	27241
@NP	p = 0.016	27241
@NP	p	27241
@NP	0.016	27245
@NP	Month 2	27254
@NP	Fig. 3C	27264
@NP	Comparison	27274
@NP	Groups	27306
@NP	Subacute	27316
@NP	Chronic Stages	27329
@NP	the transplantation delay -LRB- 1 or 4 months -RRB-	27352
@NP	the transplantation delay	27352
@NP	1 or 4 months	27379
@NP	SA and Chr rats	27395
@NP	recovering motor function	27419
@NP	the second month postgrafting	27451
@NP	the following months	27511
@NP	There	27533
@NP	no differences	27544
@NP	performance at any month postgrafting	27571
@NP	performance	27571
@NP	any month postgrafting	27586
@NP	p = 0.1-0.635	27610
@NP	p	27610
@NP	= 0.1-0.635	27612
@NP	the maximum	27634
@NP	the seventh month	27649
@NP	All transplanted rats	27668
@NP	hindlimb movement	27697
@NP	plantar placement of the paws	27716
@NP	plantar placement	27716
@NP	the paws	27737
@NP	the body weight support	27751
@NP	the test independent of the stage of transplantation -LRB- n = 10 -RRB-	27799
@NP	the test independent	27799
@NP	the stage of transplantation -LRB- n = 10 -RRB-	27823
@NP	the stage	27823
@NP	transplantation -LRB- n = 10 -RRB-	27836
@NP	transplantation	27836
@NP	n	27853
@NP	10	27857
@NP	the end of the study	27865
@NP	the end	27865
@NP	the study	27876
@NP	the transplantation delay	27901
@NP	70 % of all OEG-grafted rats	27928
@NP	70 %	27928
@NP	all OEG-grafted rats	27935
@NP	the platform by climbing from Level 3	27975
@NP	the platform	27975
@NP	Level 3	28005
@NP	10 % climbing from Level 2	28014
@NP	10 %	28014
@NP	Level 2	28032
@NP	20 % from Level 1	28045
@NP	20 %	28045
@NP	Level 1	28054
@NP	All -LRB- 100 % -RRB- rats from SA and Chr groups	28063
@NP	All -LRB- 100 % -RRB- rats	28063
@NP	100 %	28068
@NP	SA and Chr groups	28084
@NP	SA	28084
@NP	Chr groups	28091
@NP	the climbing test	28119
@NP	the fifth and fourth months	28140
@NP	these postgrafting testing periods	28186
@NP	the climbing performance	28222
@NP	the previous test period -LRB- p = 0.004 and p = 0.021 , respectively -RRB-	28270
@NP	the previous test period	28270
@NP	p = 0.004 and p = 0.021 , respectively	28296
@NP	p = 0.004	28296
@NP	p	28296
@NP	0.004	28300
@NP	p = 0.021 , respectively	28310
@NP	p	28310
@NP	= 0.021	28312
@NP	Tissue Repair	28336
@NP	SCI	28356
@NP	OB-OEG Grafts Evaluation	28363
@NP	Transplantation Effects on Scarring Macroscopically , in all transplanted rats	28391
@NP	Transplantation Effects	28391
@NP	Macroscopically , in all transplanted rats	28427
@NP	Macroscopically	28427
@NP	all transplanted rats	28447
@NP	there	28470
@NP	a white and opaque tissue	28480
@NP	the injury site	28509
@NP	cord stumps -LRB- Figs. 4A , B -RRB-	28539
@NP	cord stumps	28539
@NP	Figs. 4A , B	28552
@NP	Figs. 4A	28552
@NP	B	28562
@NP	some quantitative differences in the tissue	28577
@NP	some quantitative differences	28577
@NP	the tissue	28610
@NP	This property	28622
@NP	Non-T animals	28656
@NP	the bridge region	28680
@NP	Fig. 4C	28729
@NP	microscopy	28742
@NP	all injured spinal cords	28754
@NP	an interruption of GFAP immunolabeling	28786
@NP	an interruption	28786
@NP	GFAP immunolabeling	28805
@NP	the lesion over the entire spinal cord width	28828
@NP	the lesion	28828
@NP	the entire spinal cord width	28844
@NP	transection	28890
@NP	Fig. 5	28916
@NP	The Hoechst	28925
@NP	OB-OEG	28966
@NP	cells of the host	28976
@NP	cells	28976
@NP	the host	28985
@NP	spinal cords	28994
@NP	Figure , Supplemental Digital Content 3 , http://links.lww.com/NEN/A64	29008
@NP	Figure	29008
@NP	Supplemental Digital Content 3	29016
@NP	http://links.lww.com/NEN/A64	29048
@NP	The distribution of OB-OEG within the spinal cord	29079
@NP	The distribution	29079
@NP	OB-OEG within the spinal cord	29099
@NP	OB-OEG	29099
@NP	the spinal cord	29113
@NP	the same	29133
@NP	transplantation at the acute stage -LRB- 3 , 4 -RRB-	29172
@NP	transplantation	29172
@NP	the acute stage -LRB- 3 , 4 -RRB-	29191
@NP	the acute stage	29191
@NP	3	29208
@NP	4	29211
@NP	OB-OEG	29224
@NP	the injection sites	29245
@NP	the glial and fibrous scars	29277
@NP	They	29306
@NP	reactive astrocytes	29329
@NP	the inhibitory fibrous scar	29354
@NP	their migration	29397
@NP	Figure , Supplemental Digital Content 3 , http://links.lww.com/NEN/A64	29414
@NP	Figure	29414
@NP	Supplemental Digital Content 3	29422
@NP	http://links.lww.com/NEN/A64	29454
@NP	the effect of OB-OEG	29497
@NP	the effect	29497
@NP	OB-OEG	29511
@NP	tissue repair and scarring	29521
@NP	we	29549
@NP	the volume of GFAP-negative tissue -LRB- fibrous scar -RRB-	29563
@NP	the volume	29563
@NP	GFAP-negative tissue -LRB- fibrous scar -RRB-	29577
@NP	GFAP-negative tissue	29577
@NP	fibrous scar	29599
@NP	cavities	29618
@NP	GFAP-positive stumps -LRB- Fig. 5 -RRB-	29642
@NP	GFAP-positive stumps	29642
@NP	Fig. 5	29664
@NP	Both volumes -LRB- fibrous scar and cavities -RRB-	29673
@NP	Both volumes	29673
@NP	fibrous scar and cavities	29687
@NP	fibrous scar	29687
@NP	cavities	29704
@NP	they	29742
@NP	a measure of trauma-induced degeneration	29755
@NP	a measure	29755
@NP	trauma-induced degeneration	29768
@NP	The mean volume of GFAP-negative tissue	29797
@NP	The mean volume	29797
@NP	GFAP-negative tissue	29816
@NP	the Non-T group	29851
@NP	4.93 ± 0.96 mm3	29868
@NP	4.93 ± 0.96	29868
@NP	4.93 ±	29868
@NP	0.96	29875
@NP	mm3	29880
@NP	SA	29902
@NP	2.42 ± 0.34 mm3 , p = 0.009	29906
@NP	2.42 ±	29906
@NP	0.34 mm3 , p = 0.009	29913
@NP	0.34 mm3	29913
@NP	p = 0.009	29923
@NP	p	29923
@NP	0.009	29927
@NP	Chr	29938
@NP	2.14 ± 0.57 mm3 , p	29943
@NP	2.14 ± 0.57 mm3	29943
@NP	2.14 ±	29943
@NP	0.57 mm3	29950
@NP	p	29960
@NP	0.05	29964
@NP	Chr	29973
@NP	Fig. 5	29986
@NP	the amount of fibrosis and necrosis	30006
@NP	the amount	30006
@NP	fibrosis and necrosis	30020
@NP	nongrafted spinal cords compared with grafted ones	30056
@NP	nongrafted spinal cords	30056
@NP	grafted ones	30094
@NP	This	30108
@NP	OB-OEG	30128
@NP	the formation of new tissue and better stump healing	30143
@NP	the formation	30143
@NP	new tissue and better stump healing	30160
@NP	new tissue	30160
@NP	better stump healing	30175
@NP	the decrease of tissue loss	30203
@NP	the decrease	30203
@NP	tissue loss	30219
@NP	the case of SA rats	30234
@NP	the case	30234
@NP	SA rats	30246
@NP	spinal cord repair	30271
@NP	the lesion site	30293
@NP	There	30310
@NP	no significant differences	30321
@NP	the values between rats transplanted at SA and Chr stages -LRB- p = 0.624 -RRB-	30351
@NP	the values	30351
@NP	rats transplanted at SA and Chr stages	30370
@NP	rats	30370
@NP	SA and Chr stages	30391
@NP	SA	30391
@NP	Chr stages	30398
@NP	p	30410
@NP	0.624	30414
@NP	the efficacy of OB-OEG in spinal cord preservation at the injury	30428
@NP	the efficacy	30428
@NP	OB-OEG in spinal cord preservation at the injury	30444
@NP	OB-OEG	30444
@NP	spinal cord preservation at the injury	30454
@NP	spinal cord preservation	30454
@NP	the injury	30482
@NP	the timing of transplantation	30520
@NP	the timing	30520
@NP	transplantation	30534
@NP	The volume of GFAP-negative fibrosis and cysts	30551
@NP	The volume	30551
@NP	GFAP-negative fibrosis and cysts	30565
@NP	the maximum functional levels	30623
@NP	the maximum	30623
@NP	the climbing test -LRB- r = -0.800 ; p < 0.001 -RRB-	30656
@NP	the climbing test	30656
@NP	r = -0.800 ; p < 0.001	30675
@NP	r = -0.800 ; p <	30675
@NP	r = -0.800	30675
@NP	r	30675
@NP	-0.800	30679
@NP	p <	30687
@NP	p	30687
@NP	<	30689
@NP	0.001	30691
@NP	better tissue preservation in OB-OEGYgrafted rats	30710
@NP	better tissue preservation	30710
@NP	OB-OEGYgrafted rats	30740
@NP	axonal regeneration	30775
@NP	the lesion	30802
@NP	OB-OEG	30814
@NP	Axonal Regeneration of Brainstem Neurons Beyond the Scar Axons	30830
@NP	Axonal Regeneration	30830
@NP	Brainstem Neurons Beyond the Scar Axons	30853
@NP	Brainstem Neurons	30853
@NP	the Scar Axons	30878
@NP	the injury site	30909
@NP	more	30940
@NP	the scar than axons elongating straight beyond	30958
@NP	the scar	30958
@NP	axons elongating straight beyond	30972
@NP	axons	30972
@NP	nontreated animals	31020
@NP	more fibers within the scar than animals showing axonal regeneration	31048
@NP	more fibers	31048
@NP	the scar than animals showing axonal regeneration	31067
@NP	the scar	31067
@NP	animals showing axonal regeneration	31081
@NP	animals	31081
@NP	axonal regeneration	31097
@NP	this	31127
@NP	NFL labeling	31138
@NP	the scar not a very accurate method for quantification of axonal regeneration	31154
@NP	the scar	31154
@NP	a very accurate method for quantification of axonal regeneration	31167
@NP	a very accurate method	31167
@NP	quantification of axonal regeneration	31194
@NP	quantification	31194
@NP	axonal regeneration	31212
@NP	we	31233
@NP	an estimate of the number of fibers invading the injury region	31251
@NP	an estimate	31251
@NP	the number of fibers invading the injury region	31266
@NP	the number	31266
@NP	fibers invading the injury region	31280
@NP	fibers	31280
@NP	the injury region	31296
@NP	We	31315
@NP	NFL-immunolabeled axons	31327
@NP	the scars	31360
@NP	both grafted and Non-T spinal cords	31373
@NP	both grafted	31373
@NP	both	31373
@NP	Non-T spinal cords	31390
@NP	There	31410
@NP	no group differences	31421
@NP	the number	31445
@NP	pixels	31459
@NP	NFLpositive sprouts	31479
@NP	the scar tissue of SA , Chr , and Non-T rats -LRB- p = 0.462 -RRB-	31506
@NP	the scar tissue	31506
@NP	SA , Chr , and Non-T rats -LRB- p = 0.462 -RRB-	31525
@NP	SA	31525
@NP	Chr	31529
@NP	Non-T rats	31538
@NP	p	31550
@NP	0.462	31554
@NP	axonal regeneration	31574
@NP	the lesion	31601
@NP	we	31613
@NP	the retrograde tracer	31625
@NP	0.5 cm	31650
@NP	the rostral border of the caudal stump	31662
@NP	the rostral border	31662
@NP	the caudal stump	31684
@NP	We	31702
@NP	no inadvertent leakage or spread of the tracer	31714
@NP	no inadvertent leakage or spread	31714
@NP	the tracer	31750
@NP	the lesion	31776
@NP	the spinal cords of 3 animals	31800
@NP	the spinal cords	31800
@NP	3 animals	31820
@NP	each group	31835
@NP	The retrograde tracer	31847
@NP	the injury site or the edge of the caudal stump	31883
@NP	the injury site	31883
@NP	the edge of the caudal stump	31902
@NP	the edge	31902
@NP	the caudal stump	31914
@NP	the caudal cord	31952
@NP	Figure , Supplemental Digital Content 2 , http://links.lww.com/NEN/A63	31969
@NP	Figure	31969
@NP	Supplemental Digital Content 2	31977
@NP	http://links.lww.com/NEN/A63	32009
@NP	the tracer	32048
@NP	0.5	32075
@NP	the lesion	32084
@NP	only axons	32096
@NP	the injury region	32116
@NP	the caudal stump	32144
@NP	at least 0.5 cm	32173
@NP	the tracer	32210
@NP	all neurons containing peroxidase	32228
@NP	all neurons	32228
@NP	peroxidase	32251
@NP	neurons whose axons grew 0.5 cm or more far down into the caudal stump	32280
@NP	neurons	32280
@NP	axons	32294
@NP	0.5 cm	32305
@NP	the caudal stump	32334
@NP	Retrograde peroxidase-labeled neurons	32352
@NP	5 brainstem nuclei	32406
@NP	the initiation and modulation of locomotor patterns	32438
@NP	the initiation and modulation	32438
@NP	locomotor patterns	32471
@NP	All nuclei examined	32491
@NP	All nuclei	32491
@NP	horseradish peroxidase-labeled neurons -LRB- Fig. 6 -RRB-	32521
@NP	horseradish peroxidase-labeled neurons	32521
@NP	Fig. 6	32561
@NP	The mean total number	32570
@NP	peroxidase-labeled neurons in the brainstem of sham rats	32595
@NP	peroxidase-labeled neurons	32595
@NP	the brainstem of sham rats	32625
@NP	the brainstem	32625
@NP	sham rats	32642
@NP	16,399 ± 609 -LRB- n = 3 -RRB-	32656
@NP	16,399 ± 609	32656
@NP	n	32670
@NP	3	32674
@NP	This value	32678
@NP	5,203 ± 1,116	32693
@NP	SA rats and 6,330 ± 1,176 in the Chr group	32710
@NP	SA rats	32710
@NP	6,330 ± 1,176 in the Chr group	32722
@NP	6,330 ± 1,176	32722
@NP	the Chr group	32739
@NP	The total number of neurons regenerating their axons beyond the lesion	32754
@NP	The total number	32754
@NP	neurons regenerating their axons beyond the lesion	32774
@NP	neurons	32774
@NP	their axons	32795
@NP	the lesion	32814
@NP	more than twice	32829
@NP	OB-OEG-grafted animals -LRB- either SA or Chr -RRB-	32848
@NP	OB-OEG-grafted animals	32848
@NP	SA or Chr	32879
@NP	SA	32879
@NP	Chr	32885
@NP	Non-T rats -LRB- 2,198 ± 416 -RRB- -LRB- p < 0.018 -RRB-	32904
@NP	Non-T rats -LRB- 2,198 ± 416 -RRB-	32904
@NP	Non-T rats	32904
@NP	2,198 ± 416	32916
@NP	2,198 ±	32916
@NP	416	32924
@NP	p < 0.018	32930
@NP	p	32930
@NP	< 0.018	32932
@NP	<	32932
@NP	0.018	32934
@NP	Fig. 7	32942
@NP	Significance	32951
@NP	analysis	32981
@NP	individual nuclei	33014
@NP	reticular formation -LRB- SA , p = 0.006 ; Chr , p = 0.011 -RRB-	33033
@NP	reticular formation	33033
@NP	SA , p = 0.006 ; Chr , p = 0.011	33054
@NP	SA	33054
@NP	p = 0.006 ; Chr , p = 0.011	33058
@NP	p = 0.006	33058
@NP	p	33058
@NP	0.006	33062
@NP	Chr , p = 0.011	33069
@NP	Chr	33069
@NP	p = 0.011	33074
@NP	p	33074
@NP	0.011	33078
@NP	vestibular nucleus -LRB- SA , p = 0.018 ; Chr , p = 0.019 -RRB-	33086
@NP	vestibular nucleus	33086
@NP	SA , p = 0.018 ; Chr , p = 0.019	33106
@NP	SA	33106
@NP	p = 0.018 ; Chr , p = 0.019	33110
@NP	p = 0.018	33110
@NP	p	33110
@NP	0.018	33114
@NP	Chr , p = 0.019	33121
@NP	Chr	33121
@NP	p = 0.019	33126
@NP	p	33126
@NP	0.019	33130
@NP	locus coeruleus -LRB- SA , p = 0.018 ; Chr , p = 0.033 -RRB-	33138
@NP	locus coeruleus	33138
@NP	SA , p = 0.018 ; Chr , p = 0.033	33155
@NP	SA	33155
@NP	p = 0.018 ; Chr , p = 0.033	33159
@NP	p = 0.018	33159
@NP	p	33159
@NP	0.018	33163
@NP	Chr , p = 0.033	33170
@NP	Chr	33170
@NP	p = 0.033	33175
@NP	p	33175
@NP	0.033	33179
@NP	red nucleus -LRB- SA , p = 0.018	33187
@NP	red nucleus -LRB- SA , p	33187
@NP	0.018	33208
@NP	Chr , p = 0.011	33215
@NP	Chr	33215
@NP	p = 0.011	33220
@NP	p	33220
@NP	0.011	33224
@NP	raphe -LRB- SA , p = 0.201 ; Chr , p = 0.019 -RRB-	33236
@NP	raphe	33236
@NP	SA , p = 0.201 ; Chr , p = 0.019	33243
@NP	SA	33243
@NP	p = 0.201 ; Chr , p = 0.019	33247
@NP	p = 0.201	33247
@NP	p	33247
@NP	0.201	33251
@NP	Chr , p = 0.019	33258
@NP	Chr	33258
@NP	p = 0.019	33263
@NP	p	33263
@NP	0.019	33267
@NP	The only exception	33275
@NP	raphe nucleus of the SA group , in which the differences were not significant	33298
@NP	raphe nucleus	33298
@NP	the SA group , in which the differences were not significant	33315
@NP	the SA group	33315
@NP	the differences	33338
@NP	The Chr rats	33376
@NP	greater numbers of regenerating brainstem neurons in all nuclei than in SA rats	33399
@NP	greater numbers	33399
@NP	brainstem neurons	33431
@NP	all nuclei	33452
@NP	SA rats	33471
@NP	differences between the paradigms	33484
@NP	differences	33484
@NP	the paradigms	33504
@NP	The percentage	33540
@NP	total	33558
@NP	neurons , per nuclei and experimental group ,	33571
@NP	neurons	33571
@NP	nuclei and experimental group	33584
@NP	nuclei	33584
@NP	experimental group	33595
@NP	respect	33620
@NP	equivalent nuclei of sham animals -LRB- 100 % -RRB-	33631
@NP	equivalent nuclei	33631
@NP	sham animals -LRB- 100 % -RRB-	33652
@NP	sham animals	33652
@NP	100 %	33666
@NP	38.6 % and 31.7 %	33676
@NP	Chr and SA	33695
@NP	Chr	33695
@NP	SA	33703
@NP	comparison	33724
@NP	13.4 % of neurons of the Non-T rats	33736
@NP	13.4 %	33736
@NP	neurons of the Non-T rats	33745
@NP	neurons	33745
@NP	the Non-T rats	33756
@NP	Raphe and red nuclei	33785
@NP	Raphe	33785
@NP	red nuclei	33795
@NP	the highest number of regenerating neurons in both SA and Chr groups	33816
@NP	the highest number	33816
@NP	regenerating neurons in both SA and Chr groups	33838
@NP	regenerating neurons	33838
@NP	both SA and Chr groups	33862
@NP	both SA	33862
@NP	Chr groups	33874
@NP	The SA rats	33886
@NP	63.4 % and 46.6 % of neurons traced in raphe and red nuclei	33902
@NP	63.4 % and 46.6 %	33902
@NP	neurons traced in raphe and red nuclei	33921
@NP	neurons	33921
@NP	raphe and red nuclei	33939
@NP	the Chr rats	33979
@NP	58.2 % and 46.9 %	33999
@NP	Non-T animals	34034
@NP	the raphe and red nuclei	34049
@NP	the raphe	34049
@NP	red nuclei	34063
@NP	more spontaneous regeneration	34081
@NP	other nuclei	34116
@NP	25.9 % neurons labeled in raphe and 28.9 % in the latter	34135
@NP	25.9 % neurons	34135
@NP	raphe and 28.9 %	34160
@NP	raphe	34160
@NP	28.9 %	34170
@NP	the latter	34179
@NP	The highest incidence	34191
@NP	neurons	34229
@NP	OB-OEG grafting	34243
@NP	the locus coeruleus	34290
@NP	19 % in Chr and 13.8 % in SA compared with 2.4 % in Non-T	34311
@NP	19 %	34311
@NP	Chr and 13.8 % in SA	34318
@NP	Chr	34318
@NP	13.8 % in SA	34326
@NP	13.8 %	34326
@NP	SA	34335
@NP	2.4 % in Non-T	34352
@NP	2.4 %	34352
@NP	Non-T	34360
@NP	The percentage	34368
@NP	peroxidase-labeled neurons in the reticular formation	34386
@NP	peroxidase-labeled neurons	34386
@NP	the reticular formation	34416
@NP	vestibular nuclei of transplanted rats compared with sham animals	34444
@NP	vestibular nuclei	34444
@NP	transplanted rats compared with sham animals	34465
@NP	transplanted rats	34465
@NP	sham animals	34497
@NP	30 % to 40 %	34514
@NP	that	34540
@NP	3 times	34549
@NP	the Non-T group -LRB- Table -RRB-	34570
@NP	the Non-T group	34570
@NP	Table	34587
@NP	summary	34598
@NP	the histological results	34607
@NP	axons from several brainstem nuclei that are relevant to motor function	34642
@NP	axons	34642
@NP	several brainstem nuclei that are relevant to motor function	34653
@NP	several brainstem nuclei	34653
@NP	motor function	34699
@NP	the scars	34733
@NP	the caudal stump	34764
@NP	The extent of axonal regeneration	34782
@NP	The extent	34782
@NP	axonal regeneration	34796
@NP	rats	34831
@NP	SA and Chr phases	34852
@NP	SA	34852
@NP	Chr phases	34859
@NP	the repair efficacy of OB-OEG	34887
@NP	the repair efficacy	34887
@NP	OB-OEG	34910
@NP	delayed transplantation	34942
@NP	the stage of the healing process	34989
@NP	the stage	34989
@NP	the healing process	35002
@NP	brainstem neurons	35033
@NP	their capacity to respond positively to OB-OEG up to 4 months postlesion	35060
@NP	4 months postlesion	35113
@NP	there	35145
@NP	a window	35155
@NP	at least 4 months	35167
@NP	OB-OEG	35194
@NP	any apparent adverse effect	35226
@NP	Functional Outcome	35255
@NP	the Extent of Axonal Regeneration and Tissue Preservation	35290
@NP	the Extent	35290
@NP	Axonal Regeneration and Tissue Preservation	35304
@NP	Axonal Regeneration	35304
@NP	Tissue Preservation	35328
@NP	The maximum climbing level achieved by each rat	35348
@NP	The maximum	35348
@NP	level achieved by each rat	35369
@NP	level	35369
@NP	each rat	35387
@NP	the total number	35427
@NP	retrogradely labeled brainstem neurons -LRB- r = 0.733 ; p = 0.001 -RRB-	35447
@NP	retrogradely labeled brainstem neurons	35447
@NP	r = 0.733 ; p = 0.001	35487
@NP	r	35487
@NP	= 0.733 ; p = 0.001	35489
@NP	= 0.733	35489
@NP	p = 0.001	35498
@NP	p	35498
@NP	0.001	35502
@NP	There	35510
@NP	a correlation	35525
@NP	ability and the number of somata	35556
@NP	ability	35556
@NP	the number of somata	35568
@NP	the number	35568
@NP	somata	35582
@NP	each independent nucleus	35592
@NP	all nuclei analyzed	35624
@NP	all nuclei	35624
@NP	r = coefficients ranging from 0.784 to 0.641 ; p < 0.008	35645
@NP	r = coefficients	35645
@NP	0.784 to 0.641 ; p < 0.008	35675
@NP	0.784 to 0.641	35675
@NP	p < 0.008	35691
@NP	p <	35691
@NP	p	35691
@NP	0.008	35695
@NP	the temporary progression of functional recovery per rat	35715
@NP	the temporary progression	35715
@NP	functional recovery per rat	35744
@NP	functional recovery	35744
@NP	rat	35768
@NP	a score	35773
@NP	animal	35798
@NP	the level	35816
@NP	each month	35835
@NP	8 months posttransplantation	35853
@NP	We	35883
@NP	this period	35895
@NP	there	35915
@NP	no further improvement after the seventh month	35925
@NP	no further improvement	35925
@NP	the seventh month	35954
@NP	The final score obtained for each rat in the performance in the climbing test	35973
@NP	The final score	35973
@NP	each rat in the performance in the climbing test	36002
@NP	each rat	36002
@NP	the performance in the climbing test	36014
@NP	the performance	36014
@NP	the climbing test	36033
@NP	the total number of labeled cell bodies -LRB- r = 0.897 ; p < 0.001 -RRB-	36072
@NP	the total number	36072
@NP	labeled cell bodies	36092
@NP	r = 0.897 ; p < 0.001	36113
@NP	r = 0.897 ; p <	36113
@NP	r = 0.897	36113
@NP	r	36113
@NP	0.897	36117
@NP	p <	36124
@NP	p	36124
@NP	<	36126
@NP	0.001	36128
@NP	the number of somata	36139
@NP	the number	36139
@NP	somata	36153
@NP	each nucleus -LRB- r = 0.899-0.847 ; p < 0.001 -RRB-	36163
@NP	each nucleus	36163
@NP	r = 0.899-0.847 ; p < 0.001	36177
@NP	r = 0.899-0.847 ; p <	36177
@NP	r = 0.899-0.847	36177
@NP	r	36177
@NP	0.899-0.847	36181
@NP	p <	36194
@NP	p	36194
@NP	<	36196
@NP	0.001	36198
@NP	These positive linear correlations	36206
@NP	the concept	36261
@NP	these brainstem neurons	36278
@NP	the functional improvement of the implanted rats	36317
@NP	the functional improvement	36317
@NP	the implanted rats	36347
@NP	addition	36370
@NP	there	36380
@NP	a linear negative correlation	36390
@NP	the volume of GFAP-negative tissue -LRB- fibrosis and cavities -RRB-	36428
@NP	the volume	36428
@NP	GFAP-negative tissue -LRB- fibrosis and cavities -RRB-	36442
@NP	GFAP-negative tissue	36442
@NP	fibrosis and cavities	36464
@NP	the total number	36491
@NP	traced brainstem neurons	36511
@NP	both all -LRB- r = j0 .767 ; p < 0.001 -RRB-	36539
@NP	both all	36539
@NP	r = j0 .767 ; p < 0.001	36549
@NP	r = j0 .767 ; p <	36549
@NP	r = j0 .767	36549
@NP	r = j0	36549
@NP	.767	36555
@NP	p <	36561
@NP	p	36561
@NP	<	36563
@NP	0.001	36565
@NP	each -LRB- r = 0.780-0.697 ; p < 0.002 -RRB- nuclei	36576
@NP	r = 0.780-0.697 ; p < 0.002	36582
@NP	r = 0.780-0.697 ; p <	36582
@NP	r = 0.780-0.697	36582
@NP	r	36582
@NP	0.780-0.697	36586
@NP	p <	36599
@NP	p	36599
@NP	<	36601
@NP	0.002	36603
@NP	This	36618
@NP	the smaller	36638
@NP	the degenerative events at the injury site , the greater axonal regeneration	36650
@NP	the degenerative events	36650
@NP	the injury site , the greater axonal regeneration	36677
@NP	the injury site	36677
@NP	the greater axonal regeneration	36694
@NP	our results	36745
@NP	a role of OB-OEG on tissue preservation	36765
@NP	a role	36765
@NP	OB-OEG on tissue preservation	36775
@NP	OB-OEG	36775
@NP	tissue preservation	36785
@NP	tissue formation	36812
@NP	the lesion zone	36832
@NP	that	36848
@NP	axonal regeneration	36868
@NP	it	36895
@NP	DISCUSSION	36900
@NP	The OB-OEG	36911
@NP	functional recovery of paraplegic rats	36936
@NP	functional recovery	36936
@NP	paraplegic rats	36959
@NP	regeneration of supraspinal axons	36979
@NP	regeneration	36979
@NP	supraspinal axons	36995
@NP	the lesion	37023
@NP	rats receiving a graft after 1 and 4 months after the complete lesion	37037
@NP	rats	37037
@NP	a graft	37052
@NP	1 and 4 months after the complete lesion	37066
@NP	1 and 4 months	37066
@NP	the complete lesion	37087
@NP	functional outcome after OB-OEG transplantation at 4 months postlesion	37120
@NP	functional outcome	37120
@NP	OB-OEG transplantation at 4 months postlesion	37145
@NP	OB-OEG transplantation	37145
@NP	4 months postlesion	37171
@NP	that at either subacute or acute -LRB- 4 -RRB- time points	37211
@NP	that	37211
@NP	either subacute or acute -LRB- 4 -RRB- time points	37219
@NP	subacute	37226
@NP	acute -LRB- 4 -RRB- time points	37238
@NP	4	37245
@NP	addition	37264
@NP	axonal regeneration	37274
@NP	brainstem neurons	37297
@NP	different aspects of motor function	37336
@NP	different aspects	37336
@NP	motor function	37357
@NP	34	37373
@NP	OB-OEG-transplanted versus nontransplanted rats	37402
@NP	OB-OEG-transplanted	37402
@NP	nontransplanted rats	37429
@NP	no differences related to time posttransplantation	37462
@NP	no differences	37462
@NP	time posttransplantation	37488
@NP	the positive correlation	37523
@NP	locomotor performance and extent of axonal regeneration	37556
@NP	locomotor performance and extent	37556
@NP	axonal regeneration	37592
@NP	those brainstem neurons	37640
@NP	the motor recovery -LRB- 35-37 -RRB-	37686
@NP	the motor recovery	37686
@NP	35-37	37706
@NP	our results	37720
@NP	the effectiveness of adult OB-OEG and tissue repair	37742
@NP	the effectiveness	37742
@NP	adult OB-OEG and tissue repair	37763
@NP	the stage of the scarring processes	37814
@NP	the stage	37814
@NP	the scarring processes	37827
@NP	injured neurons	37860
@NP	their capacity to respond to OB-OEG for at least 4 months	37886
@NP	OB-OEG for at least 4 months	37915
@NP	OB-OEG	37915
@NP	at least 4 months	37926
@NP	The beneficial effects of OB-OEG	37945
@NP	The beneficial effects	37945
@NP	OB-OEG	37971
@NP	enhanced axonal regeneration , survival and tissue sparing	37999
@NP	enhanced axonal regeneration	37999
@NP	survival	38029
@NP	tissue sparing	38042
@NP	remyelination	38058
@NP	stimulation of angiogenesis	38073
@NP	stimulation	38073
@NP	angiogenesis	38088
@NP	neuroprotection -LRB- 38-41 -RRB-	38106
@NP	neuroprotection	38106
@NP	38-41	38123
@NP	a recent report	38141
@NP	OB-OEG	38171
@NP	key molecules	38186
@NP	the response	38212
@NP	wounding	38228
@NP	blood vessel development	38238
@NP	extracellular matrix formation	38264
@NP	remodeling	38299
@NP	cell adhesion -LRB- 42 -RRB-	38315
@NP	cell adhesion	38315
@NP	42	38330
@NP	the present results	38344
@NP	OB-OEG transplantation at subacute and chronic SCI stages	38376
@NP	OB-OEG transplantation	38376
@NP	subacute and chronic SCI stages	38402
@NP	subacute	38402
@NP	chronic SCI stages	38415
@NP	a reparative action via any or all of these mechanisms	38452
@NP	a reparative action	38452
@NP	any or all of these mechanisms	38476
@NP	any or all	38476
@NP	these mechanisms	38490
@NP	remyelination	38508
@NP	the present study	38542
@NP	Our study	38570
@NP	the first evidence	38589
@NP	chronic SCI	38613
@NP	OEG transplants	38644
@NP	Lu et al -LRB- 19 -RRB- and Lopez - Vales et al -LRB- 20 -RRB-	38661
@NP	Lu et al -LRB- 19 -RRB-	38661
@NP	Lu	38661
@NP	et al -LRB- 19 -RRB-	38664
@NP	et al	38664
@NP	19	38671
@NP	Lopez - Vales et al -LRB- 20 -RRB-	38679
@NP	Lopez	38679
@NP	Vales et al -LRB- 20 -RRB-	38686
@NP	Vales	38686
@NP	et al -LRB- 20 -RRB-	38692
@NP	et al	38692
@NP	20	38699
@NP	transplantation at the subacute stage , that is	38713
@NP	transplantation	38713
@NP	the subacute stage , that is	38732
@NP	the subacute stage	38732
@NP	30 and 45 days	38767
@NP	we	38807
@NP	adult OB-OEG -LRB- central -RRB-	38815
@NP	adult OB-OEG	38815
@NP	central	38829
@NP	the former study	38850
@NP	OEG	38868
@NP	lamina propria -LRB- peripheral -RRB-	38891
@NP	lamina propria	38891
@NP	peripheral	38907
@NP	the latter study	38927
@NP	neonatal bulbs	38950
@NP	It	38966
@NP	mucosal OEG	38992
@NP	the same migratory or axonal growth-promoting properties	39019
@NP	the same	39019
@NP	bulbar OEG	39079
@NP	rodents -LRB- 16-18 -RRB-	39093
@NP	rodents	39093
@NP	16-18	39102
@NP	neonatal OEG	39114
@NP	the same properties	39142
@NP	adult OEG -LRB- 24 , 43 -RRB-	39165
@NP	adult OEG	39165
@NP	24	39176
@NP	43	39180
@NP	The observation	39185
@NP	implantation of adult OB-OEG	39206
@NP	implantation	39206
@NP	adult OB-OEG	39222
@NP	recovery	39247
@NP	SCI and the lack of a decrease in efficacy	39262
@NP	SCI	39262
@NP	the lack of a decrease in efficacy	39270
@NP	the lack	39270
@NP	a decrease in efficacy	39282
@NP	a decrease	39282
@NP	efficacy	39296
@NP	a chronic stage	39318
@NP	this	39340
@NP	a more realistic paradigm for autologous cell therapy for chronic SCI	39345
@NP	a more realistic paradigm	39345
@NP	autologous cell therapy for chronic SCI	39375
@NP	autologous cell therapy	39375
@NP	chronic SCI	39403
@NP	the context of possible future clinical applications	39419
@NP	the context	39419
@NP	possible future clinical applications	39434
@NP	it	39473
@NP	OEG	39503
@NP	the OBs of adult humans -LRB- 44 -RRB- and nonhuman primates -LRB- 11 -RRB-	39528
@NP	the OBs	39528
@NP	adult humans -LRB- 44 -RRB- and nonhuman primates -LRB- 11 -RRB-	39539
@NP	adult humans	39539
@NP	44	39553
@NP	nonhuman primates	39561
@NP	11	39580
@NP	These cells	39585
@NP	standard incubators	39623
@NP	large numbers	39659
@NP	serum-containing medium	39679
@NP	A culture of a single primate OB	39704
@NP	A culture	39704
@NP	a single primate OB	39717
@NP	approximately 1.5 to 2 x 10 ^ 6 OEG	39746
@NP	approximately 1.5 to 2	39746
@NP	approximately 1.5	39746
@NP	2	39767
@NP	10 ^ 6 OEG	39771
@NP	10 ^	39771
@NP	6 OEG	39774
@NP	the short-term -LRB- 10 days in vitro -RRB-	39783
@NP	the short-term	39783
@NP	10 days	39799
@NP	an additional 20 x 10 ^ 9 cells	39818
@NP	an additional 20	39818
@NP	10 ^ 9 cells	39837
@NP	2.5 months	39870
@NP	This large number guarantees not only autologous transplantation	39882
@NP	This large number guarantees	39882
@NP	This large number	39882
@NP	guarantees	39900
@NP	autologous transplantation	39920
@NP	cells for allotransplantation and storage	39965
@NP	cells	39965
@NP	allotransplantation and storage	39975
@NP	These cells	40008
@NP	similar axonal growth-related molecules	40028
@NP	rodent cells in vitro -LRB- 11 , 44 -RRB-	40071
@NP	rodent cells	40071
@NP	vitro	40087
@NP	11	40094
@NP	44	40098
@NP	a key issue in this regard	40107
@NP	a key issue	40107
@NP	this regard	40122
@NP	the demonstration	40137
@NP	primate OB-OEG from healthy donors	40160
@NP	primate OB-OEG	40160
@NP	healthy donors	40180
@NP	age	40207
@NP	1.5 to 10 years	40216
@NP	adult	40249
@NP	locomotor recovery	40266
@NP	transplantation	40291
@NP	paraplegic rodents -LRB- 45 -RRB-	40312
@NP	paraplegic rodents	40312
@NP	45	40332
@NP	The surgical procedures	40337
@NP	human practice for unilateral bulbectomy	40386
@NP	human practice	40386
@NP	unilateral bulbectomy	40405
@NP	autologous transplantation	40435
@NP	injured spinal cords	40467
@NP	safety in nonhuman primates -LRB- 11 , 27 -RRB-	40525
@NP	safety	40525
@NP	nonhuman primates -LRB- 11 , 27 -RRB-	40535
@NP	nonhuman primates	40535
@NP	11	40554
@NP	27	40558
@NP	these data point to the OB as a reliable source of OEG for cell therapy	40574
@NP	these data point	40574
@NP	the OB as a reliable source of OEG for cell therapy	40594
@NP	the OB	40594
@NP	a reliable source of OEG for cell therapy	40604
@NP	a reliable source	40604
@NP	OEG for cell therapy	40625
@NP	OEG	40625
@NP	cell therapy	40633
@NP	A remaining and important issue	40647
@NP	A remaining	40647
@NP	important issue	40663
@NP	the present study	40692
@NP	the feasibility of OB-OEG autologous grafting for spinal cord repair	40714
@NP	the feasibility	40714
@NP	OB-OEG autologous grafting for spinal cord repair	40733
@NP	OB-OEG autologous grafting	40733
@NP	spinal cord repair	40764
@NP	The most probable clinical scenario	40784
@NP	a young adult	40826
@NP	adult patient	40843
@NP	stabilization of the clinical condition	40870
@NP	stabilization	40870
@NP	the clinical condition	40887
@NP	an accident	40916
@NP	it	40936
@NP	bulbectomy	40962
@NP	some time	40973
@NP	injury	40989
@NP	bulb removal	41013
@NP	cells	41027
@NP	at least 10 days	41054
@NP	enough OEG	41081
@NP	transplantation	41096
@NP	the experimental condition that would mimic the clinical situation most closely	41126
@NP	the experimental condition	41126
@NP	the clinical situation	41170
@NP	the implantation in the chronic situation of OEG obtained from adults	41209
@NP	the implantation	41209
@NP	the chronic situation of OEG obtained from adults	41229
@NP	the chronic situation	41229
@NP	OEG obtained from adults	41254
@NP	OEG	41254
@NP	adults	41272
@NP	We	41280
@NP	adult OB-OEG	41293
@NP	functional recovery and repair	41330
@NP	paraplegic mammals	41364
@NP	they	41388
@NP	chronic stages	41413
@NP	at least a period of 4 months	41457
@NP	at least a period	41457
@NP	4 months	41478
@NP	postlesion with no decrease in beneficial effects	41487
@NP	postlesion	41487
@NP	no decrease in beneficial effects	41503
@NP	no decrease	41503
@NP	beneficial effects	41518
@NP	the case of an autologous therapy	41541
@NP	the case	41541
@NP	an autologous therapy	41553
@NP	this window	41576
@NP	enough time	41610
@NP	OEG from the olfactory bulbs and also for patient stabilization	41644
@NP	OEG	41644
@NP	the olfactory bulbs	41653
@NP	patient stabilization	41686
@NP	the surgery	41715
@NP	our results	41739
@NP	the prospect for a future therapy	41756
@NP	the prospect	41756
@NP	a future therapy	41773
@NP	autologous implanted OB-OEG in patients experiencing a severe chronic SCI	41795
@NP	autologous	41795
@NP	OB-OEG	41816
@NP	patients experiencing a severe chronic SCI	41826
@NP	patients	41826
@NP	a severe chronic	41848
@NP	SCI	41865
@VP	occur at the injury site	519
@VP	occurs after the third month in rodents	550
@VP	promote repair of severe chronic SCI	619
@VP	has not been previously addressed	656
@VP	been previously addressed	664
@VP	previously addressed	669
@VP	were transplanted with OB-OEG 4 months after injury	719
@VP	transplanted with OB-OEG 4 months after injury	724
@VP	suggested a role for brainstem neurons in the recovery	980
@VP	did not differ after transplantation at subacute or chronic stages	1073
@VP	differ after transplantation at subacute or chronic stages	1081
@VP	is a time frame for patient stabilization and OEG preparation	1206
@VP	may offer new therapeutic opportunities for chronic SCI patients	1333
@VP	offer new therapeutic opportunities for chronic SCI patients	1337
@VP	cause permanent and irreversible functional deficits	1446
@VP	experiencing severe SCI	1537
@VP	to search for therapies aimed at curing this chronic pathology	1585
@VP	search for therapies aimed at curing this chronic pathology	1588
@VP	aimed at curing this chronic pathology	1609
@VP	curing this chronic pathology	1618
@VP	is a promising repair strategy	1709
@VP	follow spinal cord trauma -LRB- 2Y9 -RRB- , including contusion -LRB- 10 -RRB-	1868
@VP	are 13 studies that show no or limited beneficial effects	1937
@VP	show no or limited beneficial effects	1957
@VP	used for culture and transplantation	2087
@VP	become senescent and have an associated change in phenotype -LRB- 11 -RRB-	2193
@VP	become senescent	2193
@VP	have an associated change in phenotype -LRB- 11 -RRB-	2214
@VP	may compromise cell survival and/or migration -LRB- 12Y15 -RRB-	2292
@VP	compromise cell survival and/or migration -LRB- 12Y15 -RRB-	2296
@VP	is also a debated issue	2437
@VP	Mucosally derived	2462
@VP	are more accessible	2484
@VP	used adult nonsenescent OEG of bulbar origin in this study	2685
@VP	have been transplanted immediately after SCI -LRB- the acute stage -RRB-	2782
@VP	been transplanted immediately after SCI -LRB- the acute stage -RRB-	2787
@VP	transplanted immediately after SCI -LRB- the acute stage -RRB-	2792
@VP	take several weeks or even months for clinical stabilization , however	2868
@VP	would be more clinically relevant	2969
@VP	be more clinically relevant	2975
@VP	is to be used	3044
@VP	to be used	3047
@VP	be used	3050
@VP	used	3053
@VP	requires time	3076
@VP	is a more realistic paradigm	3139
@VP	has been considered to be the subacute stage -LRB- 21 , 22 -RRB-	3279
@VP	been considered to be the subacute stage -LRB- 21 , 22 -RRB-	3283
@VP	considered to be the subacute stage -LRB- 21 , 22 -RRB-	3288
@VP	to be the subacute stage -LRB- 21 , 22 -RRB-	3299
@VP	be the subacute stage -LRB- 21 , 22 -RRB-	3302
@VP	occur	3421
@VP	is after the third month in rodents -LRB- 21 , 22 -RRB-	3482
@VP	to evaluate axonal regeneration	3652
@VP	evaluate axonal regeneration	3655
@VP	grafting at the subacute stage	3784
@VP	were approved by the Ethics Committee of our institution	4114
@VP	approved by the Ethics Committee of our institution	4119
@VP	were purified 7 days after plating , as previously reported -LRB- 2 , 11 -RRB-	4396
@VP	purified 7 days after plating , as previously reported -LRB- 2 , 11 -RRB-	4401
@VP	plating , as previously reported -LRB- 2 , 11 -RRB-	4423
@VP	plating , as previously reported	4423
@VP	reported	4446
@VP	were added	4773
@VP	added	4778
@VP	were expanded for less than 2 weeks to avoid senescence -LRB- 11 -RRB-	4798
@VP	expanded for less than 2 weeks to avoid senescence -LRB- 11 -RRB-	4803
@VP	to avoid senescence -LRB- 11 -RRB-	4834
@VP	avoid senescence -LRB- 11 -RRB-	4837
@VP	detached from the flasks	4871
@VP	labeled with bisbenzimide -LRB- Hoechst 33342 ; Sigma-Aldrich Quı ' mica -RRB-	4897
@VP	described	5070
@VP	weighing 200-230 g , n = 28 -RRB-	5185
@VP	to expose the T8 to T9 segments	5284
@VP	expose the T8 to T9 segments	5287
@VP	was performed	5316
@VP	performed	5320
@VP	was opened	5362
@VP	opened	5366
@VP	were completely sectioned using microscissors	5394
@VP	sectioned using microscissors	5410
@VP	using microscissors	5420
@VP	lifted to ensure completeness of the lesion -LRB- Fig. 1A -RRB- -LRB- 4 -RRB-	5457
@VP	to ensure completeness of the lesion -LRB- Fig. 1A -RRB- -LRB- 4 -RRB-	5464
@VP	ensure completeness of the lesion -LRB- Fig. 1A -RRB- -LRB- 4 -RRB-	5467
@VP	3 -RRB- nontransplanted -LRB- Non-T -RRB-	5612
@VP	were not transplanted	5793
@VP	transplanted	5802
@VP	were injected with DMEM after 1 -LRB- n = 6 -RRB- or 4 -LRB- n = 6 -RRB- months	5819
@VP	injected with DMEM after 1 -LRB- n = 6 -RRB- or 4 -LRB- n = 6 -RRB- months	5824
@VP	were not transected	5923
@VP	transected	5932
@VP	formed underneath the resin bridge and above the spinal cord -LRB- Fig. 1D -RRB-	6061
@VP	was removed to expose the injury region	6132
@VP	removed to expose the injury region	6136
@VP	to expose the injury region	6144
@VP	expose the injury region	6147
@VP	created between the spinal cord stumps	6198
@VP	were not removed -LRB- Fig. 1E -RRB-	6238
@VP	removed -LRB- Fig. 1E -RRB-	6247
@VP	described	6417
@VP	received 0.5 µL of 50,000 OEG -LRB- 200,000 per stump -RRB-	6577
@VP	were injected with 0.5 µL of DMEM instead	6652
@VP	injected with 0.5 µL of DMEM instead	6657
@VP	were not injected	6713
@VP	injected	6722
@VP	were covered with durafilm -LRB- Ferrosan , London , UK -RRB-	6764
@VP	covered with durafilm -LRB- Ferrosan , London , UK -RRB-	6769
@VP	were administered subcutaneously	7208
@VP	administered subcutaneously	7213
@VP	was also administered and twice more every 8 hours	7341
@VP	also administered and twice more every 8 hours	7345
@VP	also administered	7345
@VP	twice more every 8 hours	7367
@VP	expressed 4 times a day until autonomous voidance and then once daily	7422
@VP	has been described -LRB- 27 -RRB-	7521
@VP	been described -LRB- 27 -RRB-	7525
@VP	described -LRB- 27 -RRB-	7530
@VP	To keep paraplegic rats in good condition	7546
@VP	keep paraplegic rats in good condition	7549
@VP	received active and passive range of motion	7594
@VP	was performed using the climbing test -LRB- Appendix 1 -RRB- once a week	7662
@VP	performed using the climbing test -LRB- Appendix 1 -RRB- once a week	7666
@VP	using the climbing test -LRB- Appendix 1 -RRB- once a week	7676
@VP	climbing test -LRB- Appendix 1 -RRB- once a week	7686
@VP	to survive for 12 months after the first surgery -LRB- lesion surgery -RRB-	7913
@VP	survive for 12 months after the first surgery -LRB- lesion surgery -RRB-	7916
@VP	subjected to a third surgery for tracer injection -LRB- see below -RRB-	7983
@VP	see below	8034
@VP	had to be maintained in good and stable clinical condition for 1 year	8092
@VP	to be maintained in good and stable clinical condition for 1 year	8096
@VP	be maintained in good and stable clinical condition for 1 year	8099
@VP	maintained in good and stable clinical condition for 1 year	8102
@VP	were not only paraplegic but also aged -LRB- 15 months old -RRB-	8327
@VP	was adapted from those used for humans -LRB- 27 -RRB-	8395
@VP	adapted from those used for humans -LRB- 27 -RRB-	8399
@VP	used for humans -LRB- 27 -RRB-	8418
@VP	used in this study	8504
@VP	is described in Appendix 1	8555
@VP	described in Appendix 1	8558
@VP	Training	8688
@VP	started when the animals were 1 month old and continued until the first surgery	8697
@VP	were 1 month old and continued until the first surgery	8722
@VP	were 1 month old	8722
@VP	continued until the first surgery	8743
@VP	started 1 month after the first surgery -LRB- lesion -RRB- -LRB- Fig. 2 -RRB-	8839
@VP	underwent a third surgery for tracer injection	8954
@VP	were allowed to survive 48 hours before perfusion	9494
@VP	allowed to survive 48 hours before perfusion	9499
@VP	to survive 48 hours before perfusion	9507
@VP	survive 48 hours before perfusion	9510
@VP	either passing through or terminating at the site of injection	9592
@VP	passing through	9599
@VP	terminating at the site of injection	9618
@VP	identifies axons regenerating at least 0.5 cm beyond the lesion	9666
@VP	regenerating at least 0.5 cm beyond the lesion	9683
@VP	were perfused with 4 % paraformaldehyde	9763
@VP	perfused with 4 % paraformaldehyde	9768
@VP	were dissected and postfixed for 5 hours	9835
@VP	dissected and postfixed for 5 hours	9840
@VP	were cut in a cryostat -LRB- -20 °C , 20-µm sections -RRB-	9967
@VP	cut in a cryostat -LRB- -20 °C , 20-µm sections -RRB-	9972
@VP	collected onto different slides	10065
@VP	processed for peroxidase detection and immunohistochemistry	10101
@VP	was sectioned at 20 µm	10209
@VP	sectioned at 20 µm	10213
@VP	were collected sequentially to locate each region of interest	10246
@VP	collected sequentially to locate each region of interest	10251
@VP	to locate each region of interest	10274
@VP	locate each region of interest	10277
@VP	spaced sections -LRB- 100 µm -RRB- were processed through the entire brainstem	10343
@VP	were processed through the entire brainstem	10368
@VP	processed through the entire brainstem	10373
@VP	To increase the signal	10551
@VP	increase the signal	10554
@VP	then stained using the Vectastain Elite ABC	10773
@VP	using the Vectastain Elite ABC	10786
@VP	containing the entire injury region and 2 segments above and below	11132
@VP	were immunostained -LRB- Appendix 2 -RRB-	11221
@VP	immunostained -LRB- Appendix 2 -RRB-	11226
@VP	were collected sequentially	11275
@VP	collected sequentially	11280
@VP	could identify the precise location of each section	11307
@VP	identify the precise location of each section	11313
@VP	see below	11395
@VP	to label reactive astroglia and to delimit the glial scar	11587
@VP	to label reactive astroglia	11587
@VP	label reactive astroglia	11590
@VP	to delimit the glial scar	11619
@VP	delimit the glial scar	11622
@VP	to stain axons	11734
@VP	stain axons	11737
@VP	to distinguish OEG	11800
@VP	distinguish OEG	11803
@VP	Labeled	12085
@VP	mounted with Fluoromount -LRB- SouthernBiotech , Birmingham , AL -RRB-	12107
@VP	coverslipped	12170
@VP	separated by 100 µm -LRB- N = 28/animal -RRB-	12310
@VP	was analyzed	12346
@VP	analyzed	12350
@VP	are GFAP negative	12432
@VP	quantified by measuring the volume of GFAP-negative tissue at the injury site	12459
@VP	measuring the volume of GFAP-negative tissue at the injury site	12473
@VP	was digitalized using a Leica microscope	12583
@VP	digitalized using a Leica microscope	12587
@VP	using a Leica microscope	12599
@VP	were outlined and measured	12696
@VP	outlined and measured	12701
@VP	using the image analysis program Metamorph , and volumes	12744
@VP	were calculated as previously described -LRB- 28 , 29 -RRB-	12800
@VP	calculated as previously described -LRB- 28 , 29 -RRB-	12805
@VP	described -LRB- 28 , 29 -RRB-	12830
@VP	multiplied by the distance to the next -LRB- 100 µm -RRB-	12924
@VP	were summed	12973
@VP	summed	12978
@VP	adjacent to those used for the quantification of tissue degeneration	13019
@VP	= 28 , also separated by 100 µm	13091
@VP	to detect axons	13230
@VP	detect axons	13233
@VP	was done within the GFAP-negative fibrous scar	13262
@VP	done within the GFAP-negative fibrous scar	13266
@VP	determined by image analysis	13357
@VP	showing anti-NFL labeling	13412
@VP	were calculated	13438
@VP	calculated	13443
@VP	were used for group comparisons	13495
@VP	used for group comparisons	13500
@VP	was used for quantifying numbers of peroxidase-traced neurons	13611
@VP	used for quantifying numbers of peroxidase-traced neurons	13615
@VP	were collected in order	13691
@VP	collected in order	13696
@VP	was known	13774
@VP	known	13778
@VP	could be identified following the Paxinos and Watson atlas -LRB- 30 -RRB-	13805
@VP	be identified following the Paxinos and Watson atlas -LRB- 30 -RRB-	13811
@VP	identified following the Paxinos and Watson atlas -LRB- 30 -RRB-	13814
@VP	avoided double or triple counting of the same neuron in adjacent sections	13908
@VP	identified by their cytoplasmic brown diaminobenzidine chromogen reaction	14017
@VP	counted using a Leica microscope	14095
@VP	using a Leica microscope	14103
@VP	used for counting in each nucleus , and per rat	14138
@VP	counting in each nucleus , and per rat	14147
@VP	using a camera -LRB- Leica DFC300 FX -RRB- attached to the microscope	14433
@VP	attached to the microscope	14466
@VP	were ordered categories -LRB- 31 -RRB-	14562
@VP	ordered categories -LRB- 31 -RRB-	14567
@VP	climbing grid	14597
@VP	placed at an increasing angle from the horizontal plane	14615
@VP	corresponding to 1 level of difficulty for the animals -LRB- Appendix 1 -RRB-	14735
@VP	named them climbing levels	14849
@VP	climbing levels	14860
@VP	were assigned	14892
@VP	assigned	14897
@VP	are most appropriate -LRB- 32 -RRB-	14985
@VP	to climb the 4 different climbing levels at both SA and Chr stages	15107
@VP	climb the 4 different climbing levels at both SA and Chr stages	15110
@VP	was used -LRB- 33 -RRB-	15222
@VP	used -LRB- 33 -RRB-	15226
@VP	observed within the same group and between groups	15486
@VP	were also made by nonparametric Kruskal-Wallis and Mann-Whitney U tests	15711
@VP	made by nonparametric Kruskal-Wallis and Mann-Whitney U tests	15721
@VP	were used because the experimental groups had fewer than 10 animals	15809
@VP	used because the experimental groups had fewer than 10 animals	15814
@VP	had fewer than 10 animals	15851
@VP	are presented as the mean T SEM	15883
@VP	presented as the mean T SEM	15887
@VP	were considered significant if p < 0.05	15942
@VP	considered significant if p < 0.05	15947
@VP	regenerating axons from individual animals	16101
@VP	achieved in the climbing test at each month during the testing period	16288
@VP	TABLE	16487
@VP	FIGURE 1	16564
@VP	were lifted to ensure completeness of the lesion	16696
@VP	lifted to ensure completeness of the lesion	16701
@VP	to ensure completeness of the lesion	16708
@VP	ensure completeness of the lesion	16711
@VP	were placed back into the vertebral channel apposing one another	16769
@VP	placed back into the vertebral channel apposing one another	16774
@VP	apposing one another	16813
@VP	sealed to the spinous processes and laminae of adjacent intact vertebrae	16969
@VP	was removed to expose the underlying spinal cord -LRB- arrow -RRB-	17117
@VP	removed to expose the underlying spinal cord -LRB- arrow -RRB-	17121
@VP	to expose the underlying spinal cord -LRB- arrow -RRB-	17129
@VP	expose the underlying spinal cord -LRB- arrow -RRB-	17132
@VP	ensheathing glia -LRB- OB-OEG -RRB- using a glass microneedle -LRB- arrow -RRB-	17295
@VP	using a glass microneedle	17321
@VP	used for transplantation and immunolabeled with anti-p75	17393
@VP	used for transplantation	17393
@VP	immunolabeled with anti-p75	17422
@VP	indicate the transection sites	17479
@VP	achieving the third climbing level , 5 months	17627
@VP	climbing level , 5 months	17647
@VP	supports its weight and propels its body to reach the horizontal platform	17751
@VP	supports its weight	17751
@VP	propels its body to reach the horizontal platform	17775
@VP	to reach the horizontal platform	17792
@VP	reach the horizontal platform	17795
@VP	is part of Video , Supplemental Digital Content 1 , http://links.lww.com/NEN/A62	17851
@VP	postgrafting	18213
@VP	Transplanted	18227
@VP	compare -LSB- A -RSB- and -LSB- B -RSB-	18547
@VP	exhibited by animals of each group	18766
@VP	Dashed	18802
@VP	showed a slight but insignificant recovery	19014
@VP	grafting	19065
@VP	behaved as Non-T animals	19093
@VP	commenced at the second month	19297
@VP	ensheathing gliaYgrafted	19474
@VP	transplanted spinal cords	19643
@VP	were bridged by white opaque tissue -LRB- A , B -RRB-	19755
@VP	bridged by white opaque tissue -LRB- A , B -RRB-	19760
@VP	were joined by a translucent membrane -LRB- C -RRB-	19825
@VP	joined by a translucent membrane -LRB- C -RRB-	19830
@VP	used for quantification of glial fibrillary acidic protein -LRB- GFAP -RRB-	19927
@VP	immunolabeled with anti-GFAP	20095
@VP	Locus coeruleus -LRB- LC -RRB-	20605
@VP	Raphe -LRB- R -RRB-	20634
@VP	bar = -LRB- A-J -RRB- 50 µm	20676
@VP	regenerating axons beyond the injury region	20762
@VP	represent the number of cell bodies per animal	21086
@VP	are the average of cell bodies per group	21139
@VP	were no significant differences between SA and Chr groups in any case	21365
@VP	died during the second surgery -LRB- DMEM injection -RRB-	21575
@VP	was eliminated from the study because it developed autotomy of its hindlimb	21765
@VP	eliminated from the study because it developed autotomy of its hindlimb	21769
@VP	developed autotomy of its hindlimb	21806
@VP	were used as Non-T controls	21855
@VP	used as Non-T controls	21860
@VP	had any complication	21928
@VP	Improved Voluntary Hindlimb Movement All transplanted and Non-T SCI rats	22071
@VP	had flaccid hindlimb paralysis	22144
@VP	started to test the climbing ability of all animals 1 month after lesion	22179
@VP	to test the climbing ability of all animals	22187
@VP	test the climbing ability of all animals	22190
@VP	were innocuous	22633
@VP	did not interfere with the normal progression of tissue changes	22652
@VP	interfere with the normal progression of tissue changes	22660
@VP	were not statistically different	22751
@VP	were considered as a single group -LRB- n = 6 -RRB-	22790
@VP	considered as a single group -LRB- n = 6 -RRB-	22795
@VP	behaved as Non-T rats in the climbing test before transplantation	22866
@VP	Grafting at the Subacute Stage All	23184
@VP	succeeded in performing the climbing test -LRB- Fig. 3A -RRB-	23240
@VP	performing the climbing test -LRB- Fig. 3A -RRB-	23253
@VP	climbing test -LRB- Fig. 3A -RRB-	23268
@VP	to climb compared with the Non-T group -LRB- p < 0.001 -RRB-	23367
@VP	climb compared with the Non-T group -LRB- p < 0.001 -RRB-	23370
@VP	climbing abilities	23479
@VP	became evident	23585
@VP	achieved Level 1	23636
@VP	improved up to Level 2 and a third reached Level 1	23687
@VP	reached Level 1	23722
@VP	postgrafting	23751
@VP	succeeded in the climbing test	23777
@VP	achieved Level 3 and 4 -LRB- 80 % -RRB-	23811
@VP	reached Level 1	23840
@VP	failed to perform any climbing level	23897
@VP	to perform any climbing level	23904
@VP	perform any climbing level	23907
@VP	climbing level	23919
@VP	exhibited some spontaneous improvement	23958
@VP	was never comparable to that of transplanted animals	24025
@VP	overcame Level 1 at the second month postinjury	24102
@VP	was the only rat that improved thereafter	24154
@VP	improved thereafter	24176
@VP	achieved the lowest climbing level	24261
@VP	with no further improvement -LRB- Fig. 3A -RRB-	24301
@VP	showed significantly better scores in the climbing test	24366
@VP	continued improving function after the fifth month	24426
@VP	improving function after the fifth month	24436
@VP	achieving Level 3 and one achieved Level 2 -LRB- Fig. 3A -RRB-	24587
@VP	achieved Level 2 -LRB- Fig. 3A -RRB-	24613
@VP	were p = 0.0145 at the sixth month and p = 0.0095 at the seventh month	24849
@VP	showed a significance of p = 0.029 at Month 6 and p = 0.020 at Month 7 and later	24946
@VP	showed a significance of p = 0.029 at Month 6 and p = 0.020 at Month 7	24946
@VP	later	25021
@VP	exhibited by OB-OEG transplanted rats	25089
@VP	was improved further at the seventh month	25228
@VP	improved further at the seventh month	25232
@VP	did not improve their climbing abilities with time	25466
@VP	improve their climbing abilities with time	25474
@VP	exhibited by some of them	25546
@VP	did not have statistical significance	25572
@VP	have statistical significance	25580
@VP	Grafting at the Chronic Stage	25637
@VP	behaved in the climbing test similar to Non-T rats	25700
@VP	recovered function more than Non-T rats -LRB- p = 0.002 -RRB-	25808
@VP	achieving the lowest climbing level -LRB- not shown -RRB-	25975
@VP	not shown	26012
@VP	showing some recovery	26070
@VP	suggesting proper integration of the graft within the cord parenchyma	26136
@VP	indicating that the transplantation can be performed safely after a chronic SCI	26210
@VP	can be performed safely after a chronic SCI	26246
@VP	be performed safely after a chronic SCI	26250
@VP	performed safely after a chronic SCI	26253
@VP	improved motor function significantly more than Non-T rats -LRB- p = 0.002 -RRB-	26304
@VP	was progressive -LRB- p = 0.016 -RRB- -LRB- Fig. 3B -RRB-	26392
@VP	had improved motor function 2 months -LRB- 6 postlesion -RRB- after grafting	26444
@VP	improved motor function 2 months -LRB- 6 postlesion -RRB- after grafting	26448
@VP	grafting	26502
@VP	achieved Level 1	26535
@VP	had improved to Level 2 or 3	26577
@VP	improved to Level 2 or 3	26581
@VP	were able to climb at least Level 1 at 4 months after grafting	26620
@VP	to climb at least Level 1 at 4 months after grafting	26630
@VP	climb at least Level 1 at 4 months after grafting	26633
@VP	achieved Level 3 , 1 achieved Level 2 , and the other , Level 1	26716
@VP	achieved Level 2 , and the other , Level 1	26736
@VP	gained their maximum functional recovery after the seventh month	26792
@VP	postgrafting than at 1 -LRB- p = 0.021 -RRB- and 2 months -LRB- p = 0.033 -RRB-	27075
@VP	remained significant	27154
@VP	started recovering motor function after the second month postgrafting	27411
@VP	continued doing so during the following months	27485
@VP	doing so during the following months	27495
@VP	reaching the maximum at the seventh month	27625
@VP	climbing from Level 3	27991
@VP	climbing from Level 2	28018
@VP	had accomplished the climbing test by the fifth and fourth months , respectively	28102
@VP	accomplished the climbing test by the fifth and fourth months , respectively	28106
@VP	Scarring Macroscopically , in all transplanted rats	28418
@VP	suggesting some quantitative differences in the tissue	28566
@VP	appeared thin and translucent -LRB- Fig. 4C -RRB-	28698
@VP	indicating that transection was complete -LRB- Fig. 5 -RRB-	28874
@VP	was complete -LRB- Fig. 5 -RRB-	28902
@VP	dye	28937
@VP	was not transferred from OB-OEG to cells of the host	28941
@VP	transferred from OB-OEG to cells of the host	28949
@VP	previously described after transplantation at the acute stage -LRB- 3 , 4 -RRB-	29145
@VP	migrated from the injection sites and invaded the glial and fibrous scars	29231
@VP	migrated from the injection sites	29231
@VP	invaded the glial and fibrous scars	29269
@VP	intermingled with reactive astrocytes	29311
@VP	To quantify the effect of OB-OEG on tissue repair and scarring	29485
@VP	quantify the effect of OB-OEG on tissue repair and scarring	29488
@VP	calculated the volume of GFAP-negative tissue -LRB- fibrous scar -RRB-	29552
@VP	formed between GFAP-positive stumps -LRB- Fig. 5 -RRB-	29627
@VP	added together because they provide a measure of trauma-induced degeneration	29719
@VP	provide a measure of trauma-induced degeneration	29747
@VP	was double in nongrafted spinal cords compared with grafted ones	30042
@VP	double in nongrafted spinal cords compared with grafted ones	30046
@VP	favored the formation of new tissue and better stump healing	30135
@VP	the decrease of tissue loss in the case of SA rats	30203
@VP	thereby helping spinal cord repair at the lesion site	30255
@VP	transplanted at SA and Chr stages	30375
@VP	seems to be independent of the timing of transplantation	30493
@VP	to be independent of the timing of transplantation	30499
@VP	be independent of the timing of transplantation	30502
@VP	seemed to help axonal regeneration across the lesion	30760
@VP	to help axonal regeneration across the lesion	30767
@VP	help axonal regeneration across the lesion	30770
@VP	tend to sprout more profusely in the scar than axons elongating straight beyond	30925
@VP	to sprout more profusely in the scar than axons elongating straight beyond	30930
@VP	sprout more profusely in the scar than axons elongating straight beyond	30933
@VP	elongating straight beyond	30978
@VP	may have more fibers within the scar than animals showing axonal regeneration	31039
@VP	have more fibers within the scar than animals showing axonal regeneration	31043
@VP	showing axonal regeneration	31089
@VP	wanted to have an estimate of the number of fibers invading the injury region	31236
@VP	to have an estimate of the number of fibers invading the injury region	31243
@VP	have an estimate of the number of fibers invading the injury region	31246
@VP	invading the injury region	31287
@VP	entering the scars in both grafted and Non-T spinal cords	31351
@VP	grafted	31378
@VP	To quantify axonal regeneration beyond the lesion	31562
@VP	quantify axonal regeneration beyond the lesion	31565
@VP	analyzing the spinal cords of 3 animals from each group	31790
@VP	did not reach the injury site or the edge of the caudal stump	31869
@VP	reach the injury site or the edge of the caudal stump	31877
@VP	was injected at 0.5 from the lesion	32059
@VP	injected at 0.5 from the lesion	32063
@VP	crossing the injury region	32107
@VP	invading the caudal stump	32135
@VP	growing at least 0.5 cm beyond	32165
@VP	could pick up the tracer	32196
@VP	pick up the tracer	32202
@VP	containing peroxidase	32240
@VP	grew 0.5 cm or more far down into the caudal stump	32300
@VP	examined	32502
@VP	contained horseradish peroxidase-labeled neurons -LRB- Fig. 6 -RRB-	32511
@VP	was 16,399 ± 609 -LRB- n = 3 -RRB-	32652
@VP	was 5,203 ± 1,116 in SA rats and 6,330 ± 1,176 in the Chr group	32689
@VP	regenerating their axons beyond the lesion	32782
@VP	were not significant	33354
@VP	regenerating brainstem neurons in all nuclei than in SA rats	33418
@VP	were not significant	33518
@VP	was 38.6 % and 31.7 % in Chr and SA , respectively	33672
@VP	were labeled	33771
@VP	labeled	33776
@VP	contained the highest number of regenerating neurons in both SA and Chr groups	33806
@VP	had 63.4 % and 46.6 % of neurons traced in raphe and red nuclei , respectively	33898
@VP	traced in raphe and red nuclei	33929
@VP	showed 58.2 % and 46.9 %	33992
@VP	labeled in raphe and 28.9 % in the latter	34149
@VP	regenerating neurons after OB-OEG grafting -LRB- up to 8-fold -RRB-	34216
@VP	was 30 % to 40 % , respectively	34510
@VP	is , 3 times more than in the Non-T group -LRB- Table -RRB-	34545
@VP	are relevant to motor function	34683
@VP	were able to cross the scars and grow beyond into the caudal stump	34714
@VP	to cross the scars and grow beyond into the caudal stump	34724
@VP	cross the scars and grow beyond into the caudal stump	34727
@VP	cross the scars	34727
@VP	grow beyond into the caudal stump	34747
@VP	remained unaltered after delayed transplantation and was independent	34917
@VP	remained unaltered after delayed transplantation	34917
@VP	was independent	34970
@VP	to respond positively to OB-OEG up to 4 months postlesion	35075
@VP	respond positively to OB-OEG up to 4 months postlesion	35078
@VP	to OB-OEG up to 4 months postlesion	35097
@VP	OB-OEG up to 4 months postlesion	35100
@VP	could be applied without any apparent adverse effect	35201
@VP	be applied without any apparent adverse effect	35207
@VP	applied without any apparent adverse effect	35210
@VP	climbing level achieved by each rat	35360
@VP	achieved by each rat	35375
@VP	analyzed	35635
@VP	ranging from 0.784 to 0.641 ; p < 0.008	35662
@VP	To estimate the temporary progression of functional recovery per rat	35703
@VP	estimate the temporary progression of functional recovery per rat	35706
@VP	summing the level achieved each month during 8 months posttransplantation	35808
@VP	achieved each month during 8 months posttransplantation	35826
@VP	was no further improvement after the seventh month	35921
@VP	obtained for each rat in the performance in the climbing test	35989
@VP	contributed to the functional improvement of the implanted rats	36302
@VP	suggest a role of OB-OEG on tissue preservation	36757
@VP	tissue formation at the lesion zone	36812
@VP	may facilitate axonal regeneration across it	36853
@VP	facilitate axonal regeneration across it	36857
@VP	receiving a graft after 1 and 4 months after the complete lesion	37042
@VP	did not differ from that at either subacute or acute -LRB- 4 -RRB- time points	37191
@VP	differ from that at either subacute or acute -LRB- 4 -RRB- time points	37199
@VP	are involved in different aspects of motor function	37320
@VP	involved in different aspects of motor function	37324
@VP	related to time posttransplantation	37477
@VP	having contributed to the motor recovery -LRB- 35-37 -RRB-	37664
@VP	contributed to the motor recovery -LRB- 35-37 -RRB-	37671
@VP	was not affected by the stage of the scarring processes	37794
@VP	affected by the stage of the scarring processes	37802
@VP	preserved their capacity to respond to OB-OEG for at least 4 months	37876
@VP	to respond to OB-OEG for at least 4 months	37901
@VP	respond to OB-OEG for at least 4 months	37904
@VP	could be exerting a reparative action via any or all of these mechanisms	38434
@VP	be exerting a reparative action via any or all of these mechanisms	38440
@VP	exerting a reparative action via any or all of these mechanisms	38443
@VP	was not examined in the present study , however	38522
@VP	examined in the present study , however	38530
@VP	provides the first evidence that chronic SCI can be repaired by OEG transplants	38580
@VP	can be repaired by OEG transplants	38625
@VP	be repaired by OEG transplants	38629
@VP	repaired by OEG transplants	38632
@VP	is	38757
@VP	were obtained from lamina propria -LRB- peripheral -RRB-	38872
@VP	obtained from lamina propria -LRB- peripheral -RRB-	38877
@VP	do not exhibit the same properties as adult OEG -LRB- 24 , 43 -RRB-	39127
@VP	exhibit the same properties as adult OEG -LRB- 24 , 43 -RRB-	39134
@VP	used in a chronic stage	39310
@VP	makes this a more realistic paradigm for autologous cell therapy for chronic SCI	39334
@VP	easily cultured in standard incubators	39604
@VP	expanded in large numbers using serum-containing medium	39647
@VP	using serum-containing medium	39673
@VP	can be obtained after 2.5 months	39848
@VP	be obtained after 2.5 months	39852
@VP	obtained after 2.5 months	39855
@VP	but also provides cells for allotransplantation and storage	39947
@VP	also provides cells for allotransplantation and storage	39951
@VP	ranging in age from 1.5 to 10 years -LRB- young to mature adult -RRB-	40196
@VP	to mature adult	40239
@VP	mature adult	40242
@VP	been determined and checked for safety in nonhuman primates -LRB- 11 , 27 -RRB-	40493
@VP	determined and checked for safety in nonhuman primates -LRB- 11 , 27 -RRB-	40498
@VP	was the feasibility of OB-OEG autologous grafting for spinal cord repair	40710
@VP	requires stabilization of the clinical condition after an accident	40861
@VP	seems safer to perform bulbectomy some time after injury	40939
@VP	to perform bulbectomy some time after injury	40951
@VP	perform bulbectomy some time after injury	40954
@VP	need to be grown for at least 10 days to obtain enough OEG for transplantation	41033
@VP	to be grown for at least 10 days to obtain enough OEG for transplantation	41038
@VP	be grown for at least 10 days to obtain enough OEG for transplantation	41041
@VP	grown for at least 10 days to obtain enough OEG for transplantation	41044
@VP	to obtain enough OEG for transplantation	41071
@VP	obtain enough OEG for transplantation	41074
@VP	would mimic the clinical situation most closely	41158
@VP	mimic the clinical situation most closely	41164
@VP	is the implantation in the chronic situation of OEG obtained from adults	41206
@VP	obtained from adults	41258
@VP	are transplanted at chronic stages	41393
@VP	transplanted at chronic stages	41397
@VP	Grafting	41429
@VP	can be delayed for at least a period of 4 months	41438
@VP	be delayed for at least a period of 4 months	41442
@VP	delayed for at least a period of 4 months	41445
@VP	implanted OB-OEG in patients experiencing a severe chronic SCI	41806
@VP	experiencing a severe chronic SCI	41835
